1. Introduction {#S1}
===============

Fear, anxiety and trauma-related disorders are associated with excessive fear reactions triggered by specific objects, situations or internal and external cues in the absence of any actual danger, and often include an inability to extinguish learned fear and to show adequate safety learning \[([@R239]; [@R347]; [@R350]; [@R349]; [@R534]) reviewed in ([@R223]) and ([@R258])\]. Pathological fear and anxiety occur in a range of psychiatric conditions, including various types of phobia (e.g. social phobia, agoraphobia or specific phobia), panic disorder with/without agoraphobia, obsessive--compulsive disorder (OCD), generalized anxiety (GAD) and post-traumatic stress disorder (PTSD) ([@R118]; [@R229]). These disorders comprise the most common mental disorders and are estimated to have a life-time prevalence of up to 28% among western populations ([@R247]; [@R246]; [@R542]). In addition to the personal suffering of patients, the economic burden caused by anxiety disorders is heavy ([@R182]).

Available pharmacological and psychotherapeutic treatments ([@R24]) which aim to reduce fear and anxiety are associated with decreased symptom severity, but up to 40% of anxiety patients show only partial long-term benefit, and a majority of them fail to achieve complete remission ([@R25]; [@R213]; [@R487]) clearly underlining the need for further improvement. Current pharmacological approaches either induce rapid anxiolytic effects (e.g. benzodiazepines, some antipsychotics) or require prolonged, chronic treatment (e.g. antidepressants) to attenuate symptoms of pathological fear and anxiety. Commonly employed psychotherapeutic interventions apply cognitive behavioral strategies and exposure techniques to help patients overcome the maladaptive beliefs and avoidance behaviors that reinforce the pathology related to fear-eliciting cues. Meta-analyses show that cognitive behavioral therapy (CBT) does have efficacy for several anxiety disorders, including PTSD, but patients have difficulty bearing the demanding and exhausting process of therapy and many who do manage to cope with it respond only partially and often relapse with time ([@R79]).

One strategy to improve CBT is to augment psychotherapy with ad-junctive pharmacological treatments. Early attempts at combining 'CBT' with anxiolytic medications \[e.g. benzodiazepines (BZD)\] showed that the combination was no more effective \[in some instances even counterproductive ([@R321]; [@R539])\] than psycho- or pharmacotherapy alone \[for details see ([@R121]; [@R214]; [@R388],[@R389]; [@R436])\]. However, at least in some cases, this failure may have reflected idiosyncratic effects of the drugs tested (especially BZDs) rather than utility of the strategy itself, and there has been an intense search to identify agents that serve as more effective adjuncts to CBT. The preclinical assay most frequently used in this search is fear extinction -- the focus of this current review. Extinction of fear following Pavlovian fear learning ([@R405]) in animals is procedurally similar to exposure-based CBT ([@R351]). We will briefly outline different aspects of Pavlovian fear learning \[ (which is thought to be involved in the etiology and maintenance of anxiety disorders, e.g. ([@R11])\] and extinction highlighting the key processes that could be targeted to augment fear extinction (see [Fig. 1](#F1){ref-type="fig"} for an overview).

1.1. Fear and fear extinction {#S2}
-----------------------------

Experimentally, fear conditioning occurs when a previously neutral stimulus \[conditioned stimulus (CS) -- such as a tone or light\] is paired with an aversive, unconditioned stimulus (US -- e.g. electric shock to the forearm in humans, mild foot shock in rodents), resulting in a CS-US association whereby the CS alone elicits a conditioned fear response (e.g. freezing in rodents or increased skin conductance in humans). Following a successful CS--US association, fear memories require consolidation, a process involving a cascade of molecular and cellular events that alter synaptic efficacy, as well as a prolonged systems level interaction between brain regions, to stabilize the memory ([@R329]). Once consolidated, fear memories, reactivated by presenting the CS, are destabilized to render the original fear memory liable to pharmacological/ behavioral interference (see overview in [Fig. 1](#F1){ref-type="fig"}) and this is then followed by a second phase of molecular and cellular events to re-stabilize (re-consolidate) the (adapted) memory ([@R370]).

Fear memories can be attenuated by various processes and interventions (including pharmacological and psychological approaches), some producing temporary blunting of fear behaviors and others causing more long-lasting relief. Interfering with the re-consolidation by inhibiting molecular and cellular events supporting fear memory re-stabilization \[[Fig. 1C](#F1){ref-type="fig"}, ([@R287]; [@R370])\], for example with β-adrenoceptor blockers ([@R105]; [@R251]), has been proposed as a clinical approach to alleviating fear memories. For discussion on this and other means of reducing fear (e.g. via US habituation) we refer the reader to some excellent prior reviews ([@R164]; [@R457]). Other potential ways to relieve fear include safety learning ([@R258]; [@R438]) and erasure-like mechanisms such as destruction of erasure-preventing perineuronal nets ([@R158]).

Alternatively, fear memories can also be extinguished. Fear extinction, a process originally described by Pavlov ([@R405]), entails repeated exposure to anxiety-provoking cues to establish a new memory that counters the original fear memory. The process is highly relevant to fear, anxiety and trauma-related disorders which are associated with negative emotional reactions triggered by specific objects, situations or internal and external cues that are excessive to the actual danger posed. Moreover, extinction in animals is procedurally similar to forms of CBT that rely on exposure to anxiety-provoking cues (see [Fig. 1](#F1){ref-type="fig"}) ([@R351]), and anxiety disorders are associated with an inability to extinguish learned fear and to respond adequately to safety signals ([@R239]; [@R347]; [@R350]; [@R349]; [@R534]) \[reviewed in ([@R223])\]. Thus, fear extinction has considerable translational utility. The key processes that can be targeted to pharmacologically augment fear extinction are summarized in [Fig. 1](#F1){ref-type="fig"}.

Extinction is a learning process driven by violation of the original CS=US contingency (termed 'prediction error' for review see ([@R406]; [@R339]) \], but it also contains other elements including habituation and desensitization some also say era-sure/destabilization ([@R299]). Some authors therefore favor the term 'relearning' over extinction \[for discussion see ([@R434])\]. As with fear learning, extinction occurs in two phases: extinction acquisition and extinction consolidation. The decrement in the fear response during'extinction training' is also termed '*within-session extinction*'. Similar to fear memory, stabilization of the extinction memory requires both a cascade of overlapping, but dissociable, molecular and cellular events \[for review see ([@R368]; [@R386]) \] that alter synaptic efficacy and brain systems-level interactions ([@R399]). The strength of extinction memory can be assessed at some interval (usually \>1 day) after extinction training in "*extinction retrieval*" sessions (also termed '*extinction retention*' *or* '*extinction expression*', *but note that we use the term "extinction retrieval" throughout this review*).

That extinction memories are prone to re-emergence (due to insufficient 'longterm extinction') indicates that the original fear memory is still in place and the extinction memory is weaker/more labile than the fear memory. This may be particularly true of older ('remote') fear memories ([@R519]). The re-emergence of extinguished fear occurs under multiple circumstances: (i) renewal, when the CS is presented in a different context to that in which extinction training occurred; (ii) reinstatement, when the original US or another stress-or is given unexpectedly; and (iii) spontaneous recovery, when a significant period of time has elapsed following successful extinction training ([@R207]; [@R368]). The likelihood of fear re-emergence is dependent on the strength of the extinction memory which is also determined by the type of extinction protocol used see e.g. ([@R266]; [@R294]). Spontaneous recovery ([@R443],[@R444]; [@R453]), reinstatement ([@R453]) and renewal ([@R124]) are all observable in clinical settings, and can be readily exploited in the laboratory to identify drugs and other interventions that can prevent fear re-emergence in animals and relapse in humans ([@R524]).

Our goal in the current review is to offer a comprehensive overview of preclinical work on the possible pharmacological approaches (see [Box 1](#BX1){ref-type="boxed-text"} for an overview) to augment fear extinction and protect against the re-emergence of fear, and to discuss the potential translational value of these candidates as adjuncts to exposure-based CBT in anxiety patients.

2. Neuronal substrates of fear extinction {#S3}
=========================================

Using a number of complementary techniques (including electro-physiology, immediate-early gene mapping, tracing studies, lesioning/ inactivation approaches and optogenetics) research is revealing the complex and interconnected brain circuitry mediating fear extinction. Several key brain areas including the amygdala (AMY), hippocampus (HPC), medial prefrontal cortex (mPFC), periaqueductal gray (PAG), bed nucleus of the stria terminalis and others have been implicated in extinction \[for recent detailed reviews see ([@R122]; [@R126]; [@R207]; [@R254]; [@R368]; [@R386]; [@R399])\]. Of these, we focus on the AMY, HPC and mPFC as major, well-defined components of the fear circuitry (see [Fig. 2](#F2){ref-type="fig"}).

While the AMY and the mPFC are crucial for the formation and maintenance of fear extinction memories, the HPC, linked with the mPFC and the AMY ([@R399]), processes contextual information linked with extinction ([@R386]). Altering these hippocampal contributions to extinction memory or mimicking the hippocampal response within the extinction context (see below) may be mechanisms that render extinction context-independent. The AMY is a core hub in fear extinction processing. Data in rodents and humans suggest sustained AMY activity in extinction-impaired individuals, possibly resulting from a failure to engage pro-extinction circuits in cortical areas and subregions of the AMY \[reviewed in ([@R223])\]. Different AMY subregions and neuronal populations have differential contributions to extinction. The centromedial AMY (CeM) is the major output station of the AMY that drives fear via its connections to the hypothalamus and brainstem regions ([@R133]; [@R284]; [@R319]), and its responding is modulated following extinction via intra-amygdala and remote inputs. Extinction training has been shown to cause a rapid reduction of CS-evoked responses of lateral AMY (LA) neurons possibly via depotentiation of thalamic inputs ([@R122]). The basal AMY (BA) contains extinction-encoding neurons which drive GABAergic cells in the medial intercalated cell masses (ITC) and neurons in the centrolateral AMY (CeL) to inhibit the CeM and the expression of fear ([@R122]; [@R206]). Following from these initial findings, additional studies involving optogenetic approaches, have shown that a subpopulation of the BA pyramidal neurons which express the Thy1 gene may mark the extinction neuron subpopulation ([@R237]).

It is also becoming apparent that different ITCs are part of a GABAergic feed-forward relay station interconnecting AMY nuclei with distinct networks within the ITCs that are engaged in particular fear stages exerting different influences on extinction ([@R53]; [@R122]; [@R535]). Separate neuronal populations in the CeL have been found to have contrasting roles in fear and fear extinction. CeL-OFF neurons (PKCδ+ phenotype) inhibit fear-promoting CeM neurons, while CeL-ON (PKCδ- phenotype) cells stimulate fear-promoting CeM neurons ([@R81]; [@R196]). Additionally, a very recent finding suggests that a subpopulation of neurons within the CeM -- that of the Tac2 peptide-expressing cells -- is critically involved in fear learning and fear expression ([@R12]).

Another important node within the extinction circuitry is the mPFC, which shares strong interconnections with the HPC and the AMY. Fear extinction recruits the ventral segment of the mPFC, the infralimbic (IL) subdivision \[the rodent correlate of the human ventromedial PFC (vmPFC)\] which projects to BA extinction and ITC neurons and can thereby inhibit the activity of CeM fear output neurons \[reviewed in ([@R10]; [@R459])\]. When a conditioned cue following extinction is presented in the extinction (therapy) context, the HPC activates the IL (an activation which is absent or less in a novel context), supporting subsequent CeM inhibition ([@R207]). The IL subdivision is involved in the consolidation of extinction memory and synaptic plasticity in this region is crucial for successful extinction retrieval ([@R363]). Impaired extinction has been associated with relatively low activity in IL neurons, and successful extinction with relatively high IL neuronal activity \[reviewed in ([@R223])\]. The region of the mPFC neighboring the IL \[the prelimbic cortex (PL) in rodents and the dorsal anterior cingulate in humans\] plays an opposite role to the IL in regulating fear and extinction \[reviewed in ([@R351])\]. The PL interacts with BA fear neurons, augmenting output of the basolateral amygdaloid complex (BLA) and hence CeM activity ([@R459]).

There is now strong evidence from both animal and human studies that these various components of the neural circuit underlying extinction are functionally disturbed in individuals with impaired extinction (reviewed in ([@R223]) and importantly that successful extinction in animals ([@R535]) and exposure therapy in humans ([@R198]) can correct these abnormalities by triggering a lasting reorganization of this network.

3. Neurochemical and molecular substrates of fear extinction {#S4}
============================================================

Research is revealing that the activity of a number of specific intra-cellular signaling cascades \[reviewed in ([@R386])\] carrying biological information from the cell surface to the nucleus, is the key to successful extinction by modulating gene transcription and ultimately promoting synaptic plasticity in extinction-relevant brain regions. The consolidation of extinction memories requires new protein synthesis initiated by molecular signaling cascades within the AMY, HPC and mPFC. The extinction-related molecular signaling and gene expression modulation can differ considerably in these brain areas ([@R67]). Key molecules in the amygdala include calcium (Ca2+) influx via NMDA-receptors \[in an interaction with α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptors\] and VGCCs-mediated activation of Ca2+/calmodulin-dependent protein kinase II (CaMKII) and kinases such as Ca2+ /phospholipid-dependent protein kinase (PKC), and cAMP-dependent protein kinase A (PKA). Once activated, these kinases merge into a common mitogen-activated protein kinase (MAPK)/extracellular regulated kinase (ERK) signaling pathway initiating cAMP response element binding (CREB) phosphorylation and transcription of plasticity proteins \[reviewed in ([@R386], see [Fig. 3](#F3){ref-type="fig"} for overview\]. Aspects of this intracellular signaling seem to be disrupted in deficient extinction, as exemplified by the correlation of impaired extinction with reduced ERK activity in extinction-relevant brain areas ([@R63]; [@R208]; [@R231]). Similarly, aberrant expression of memory-related genes in these areas is correlated with impaired extinction ([@R223]).

To enable selective therapeutic targeting, an important aim in the extinction field is to identify neural mechanisms and intracellular pathways in fear extinction that are different from those involved in fear memory formation. Many of the intracellular mechanisms are similar, however there are also a number of distinct processes and features in fear vs fear extinction learning, including differences in protein synthesis dependence, in brain area- and neuronal population-specific localization and recruitment of signaling pathways, in time course of recruitment, in distinct involvement of certain isoforms of key signaling components (e.g. ERK1 vs ERK2) and resulting gene expression ([@R67]; [@R175]; [@R275]; [@R516]). While there are examples of the direct targeting of pharmacologically important components of the aforementioned intracellular signaling, e.g. the MAPK/ERK pathway ([@R139]; [@R208]; [@R305]) to modulate fear extinction, they were mainly targeted indirectly via membrane receptors e.g. ([@R63]; [@R325]) or ion channels ([@R93]; [@R231]). These findings have stimulated the hypothesis that boosting specific synaptic plasticity mechanisms by pharmacological means may constitute novel drug targets to promote fear extinction. Indeed, as outlined below, systemic and brain region specific drug studies have identified a number of promising compounds which augment the behavioral and neurobiological effects of fear extinction. The results of these studies are building a framework upon which novel therapeutic interventions to facilitate the efficacy of CBT may be rationally developed and which may ultimately help to enhance symptom remission and recovery.

4. Pharmacologically enhancing extinction {#S5}
=========================================

4.1. Serotonergic system {#S6}
------------------------

The serotonin (5-HT) system is positioned to modulate the extinction circuitry via ascending 5-HT projections arising from midbrain raphe nuclei that innervate certain brain structures including the AMY (BLA \> LA ≫ CeA), the HPC, the mPFC and the bed nucleus of the stria terminalis \[reviewed in ([@R49])\]. The acquisition and expression of conditioned fear increases 5-HT release in the BLA, mPFC and dPAG ([@R245]; [@R560]; [@R562]) though possible changes in 5-HT release during acquisition and consolidation of fear extinction have not been reported to the best of our knowledge.

There are 16 5-HT receptor subtypes classified into 7 receptor families (5-HT~1--7~) ([Fig. 4](#F4){ref-type="fig"}). All 5-HT receptors, excluding the 5-HT~3~ family -- a member of a superfamily of ligand-gated ion channels, are metabotropic, coupled to Gs (5-HT~6~ and 5-HT~7~), Gi/0 (5-HT~1~, 5-HT~4~ and 5-HT~5~) or Gq (5-HT~2~) proteins.

To date, research has largely focused on the role of 3 of the 5-HT receptors in fear extinction; namely 5 HT~1A~, 5-HT~2~ and 5-HT~3~ ([Table 1](#T1){ref-type="table"}, [Fig. 4](#F4){ref-type="fig"}). Selective activation of 5-HT~1A~ ([@R447]; [@R528]) or 5-HT~2A~ receptors ([@R65]; [@R564]) enhances extinction. This might occur via 5-HT~1A~ and 5-HT~2A~ receptors expressed in the mPFC and the LA ([@R68]; [@R87]; [@R450]). Both of these receptors regulate mPFC and LA excitability via direct activation of pyramidal cells and/or GABAergic interneurons ([@R303]; [@R426]; [@R494]). 5HT~2A~ agonists increase presynaptic glutamate release ([@R6]) and increase NMDA receptor sensitivity ([@R16]) and these are mechanisms well characterized as being important in extinction (see Section 4.4 *Glutamatergic system*).

The roles in extinction of other 5-HT receptors or other components of the 5-HT system, such as melatonin (([@R226]) have not been extensively explored. For example, recent work indicating that the 5-HT~7~ receptor regulates emotional memories ([@R128]), has not been followed up with studies on extinction. However, 5-HT~3~ receptors have been also associated with fear extinction mechanisms ([Table 1](#T1){ref-type="table"}). While 5-HT~3~ antagonists have been found to improve extinction ([@R400]), constitutive deletion of 5-HT~3~ receptors has the opposite effect, possibly due to developmental changes in the 5-HT system ([@R257]).

Despite the limited knowledge that we have so far regarding specific 5-HT receptor contributions to extinction, chronic treatment with SSRIs to enhance 5-HT availability is the first-line therapy for many anxiety disorders. Acute SSRI treatment induces anxiogenic effects, which can be prevented with 5-HT~2C~ antagonists in rodents and mimicked by 5-HT~2C~ agonists administered systemically ([@R18]; [@R448]) or locally into the BLA ([@R61]). Chronic treatment with some SSRIs (e.g., fluoxetine) but not all (e.g., citalopram) enhances extinction in rodents ([Table 1](#T1){ref-type="table"}) \[for a recent review see ([@R49])\], including models of impaired extinction \[([@R60]; [@R142]) see [Table 1](#T1){ref-type="table"}\]. Venlafaxine -- a combined 5-HT and noradrenaline reuptake inhibitor with weaker affinity to the noradrenaline transporter ([@R391]) -- also improves extinction retrieval and protects against fear reinstatement in rodents ([@R554]). Chronic fluoxetine treatment does not strengthen fear conditioning or fear expression ([@R60]) suggesting relative selectivity for extinction. Another clinically relevant attribute of chronic fluoxetine treatment is the protection it provides against the return of fear, as assayed by spontaneous recovery or fear renewal ([@R108]; [@R109]; [@R243]). Furthermore, an important molecular mechanism through which fluoxetine produces extinction-associated reductions in fear may be the transformation of adult plasticity mechanisms to a juvenile state ([@R243]).

These encouraging preclinical discoveries will hopefully stimulate comprehensive clinical assessment of the efficacy of SSRIs in augmenting CBT in anxiety patients ([Table 1A](#T2){ref-type="table"}). There have been small-scale clinical trials showing, for example, that paroxetine augments fear reductions (assessed using CAPS scores) and is associated with higher remission rates when combined with CBT in PTSD patients as compared with a placebo/CBT group. An optional treatment maintenance for an additional 12 weeks revealed that symptomatic improvements were long-lasting and consistent although no further improvements could be detected. However, this may have been due to enhanced drop-out of patients who had remitted in earlier phases of the study ([@R455]). More evidence is available in panic disorder ([Table 1](#T1){ref-type="table"}). There is evidence that chronic SSRI treatment (fluvoxamine, paroxetine) increases CBT-induced fear reductions in panic disorder patients ([@R98]; [@R382]). However results concerning the extinction-augmenting ability of SSRIs are not consistent as SSRIs, including fluvoxamine, fluoxetine, sertraline and paroxetine, have failed to demonstrate efficacy in primary outcomes \[clinical global impression; ([@R34]; [@R92]; [@R197]; [@R260]; [@R488]). Despite their common effect of serotonin transporter inhibition, SSRIs are known to differ with regard to their pharmacological properties. Along these lines, some SSRIs (e.g. paroxetine) show additional noradrenaline transporter-inhibiting properties via their metabolites ([@R391]), while others (e.g. citalopram) show continued selectivity for the serotonergic system ([@R110]). In this respect, differential effect sizes of SSRIs are to be expected.

Nevertheless, a number of outstanding questions remain, including that concerning the specificity of SSRIs in augmenting fear extinction as opposed to fear learning (as observed with fluoxetine in preclinical models; see above). In this respect, the finding that prior fear conditioning administration of escitalopram augments extinction learning in healthy volunteers without influencing fear acquisition ([@R47]) may hint at a potential selectivity of SSRIs to preferentially engage extinction mechanisms. However, this remains to be tested.

In summary, the clinical studies performed so far have demonstrated that SSRI augmented psychotherapy holds some benefits for panic disorder patients and possibly for PTSD and SAD patients. However, further studies of different SSRIs in larger patient cohorts will be needed, as well as adequate follow-up time to reveal long-term effects, before more definite conclusions can be drawn. Until such studies, as well as studies investigating receptor selective approaches are available, it seems rational to recommend combined treatment involving exposure-based psychotherapy together with antidepressants including SSRIs such as fluoxetine, as there is more evidence supporting than disproving such a strategy at the moment.

4.2. Dopaminergic system {#S7}
------------------------

An increasing amount of evidence suggests that dopamine (DA) signaling has an important role in extinction mechanisms ([Fig. 5](#F5){ref-type="fig"}) \[for a recent detailed review, see ([@R3])\]. The DAergic system innervates forebrain extinction circuits through ascending mesocortical/limbic DAergic projections from the ventral tegmental area targeting certain brain regions including the mPFC, HPC and AMY ([@R412]; [@R414]; [@R531]). There is increased dopamine release in the mPFC during and following extinction training ([@R228]) and boosting DAergic signaling with DA precursors or DA-releasing drugs facilitates extinction consolidation ([@R2]; [@R185]) and can rescue impaired fear extinction in female rats ([@R432]). Conversely, reducing DAergic transmission by lesioning mesocortical DAergic projection neurons (with 6-OH-DOPA) impairs extinction memory formation ([@R136]; [@R361]) (see summary in [Table 2](#T3){ref-type="table"}). More recently, there have been further insights into the mechanisms of how and where DAergic signaling can influence fear extinction have been made. These studies (see [Table 2](#T3){ref-type="table"} and below) have revealed a complex two-pronged feature of DAergic signaling that can (i) gate the expression of fear, and (ii) influence fear extinction consolidation mechanisms.

Dopamine receptors are metabotropic and in the classical view, coupled to either G~s~ (increased cAMP, D1-like) or G~i/0~ (decreased cAMP, D2-like) proteins. However, DAergic signals can also be transduced via Phospholipase C (PLC) activation (enhanced DAG, IP3) mediated by D1-like Gα proteins, by D2-like Gβγ subunits or by receptors forming D1/D2 heteromers ([@R132]; [@R288]) \[for review see ([@R3])\]. The D1-class receptor signaling modulates the excitability of BLA parvalbumin-positive interneurons ([@R32]; [@R262]; [@R304]) and ITCs ([@R315]). In concert with D2-like receptors in the CeL/CeC ([@R408]), DAergic signaling exerts tight control over CeM-mediated expression of fear. To date, however, pharmacological manipulation of DAergic signaling in the AMY has produced conflicting results with regard to extinction ([@R138]; [@R210]) (see [Table 2](#T3){ref-type="table"}).

Preclinical work has aimed to clarify the role of DA receptor activity in extinction. However, research has been largely complicated by the lack of receptor subtype-selective compounds, leaving many investigations reliant on drugs acting on D1-like (D1, D5) and D2-like (D2, D3, D4) receptor subfamilies. One reliable finding, however, is that DA antagonism (see [Table 2](#T3){ref-type="table"}) specifically in the mPFC impairs the retrieval of extinction memories ([@R210]; [@R362]; [@R411]). In this case, DAergic effects on glutamatergic NMDA receptor signaling may be involved. As discussed below (Section 4.4 *Glutamatergic system*), NMDA receptor-mediated burst activity of mPFC neurons is associated with stabilization of extinction memories ([@R51]) and D1-like receptor agonists facilitate NMDA receptor currents via Gs mediated increases in adenylate cyclase (AC) activity ([@R479]). There is also the possibility that D2 receptor mechanisms in the PFC support extinction, as ([@R362]) showed that a pre-extinction IL injection of the D2 antagonist raclopride impaired the consolidation of extinction memory. However, following systemic administration of the (less selective) D2 receptor antagonist sulpiride, accelerated extinction was found ([@R416]).

In summary, the results of preclinical studies do not yet fully clarify the specific DA receptor or receptor class mediating the extinction augmenting effect of enhanced dopaminergic signaling. Work still needs to be done on the use of receptor-selective agonists and antagonists, as well as biased ligands (showing functional selectivity for either AC or PLC signal transduction pathways) to reveal receptor-specific functions and their modulation of downstream signaling cascades in extinction. Pharmacologically increasing the DA tone promotes extinction. L-DOPA administration following extinction training enhances fear extinction in mice and healthy humans, rendering extinction resistant to fear renewal, reinstatement and spontaneous recovery ([@R185]). L-DOPA is a precursor for all catecholamines, but preferentially enhances dopaminergic turnover in the frontal cortex ([@R97]), eliciting D1- and D2-like receptor responses ([@R518]). Indeed, L-DOPA augments extinction-related neural activity in the mPFC (IL) of mice and increases mPFC functional coupling in humans ([@R185]). These findings have immediate translational potential because L-DOPA is a US Food and Drug Administration-approved compound used in the treatment of Parkinson\'s disease, typically in combination with carbidopa (a peripheral decarboxylase inhibitor) to maximize central availability and minimize peripheral side effects. While there are abuse related issues with any DA enhancer, this could be mitigated by supervised, acute treatment during CBT. Encouragingly, a small-scale clinical trial found improved efficacy of psychotherapy in treatment-resilient PTSD patients by administration of another DA-enhancing drug, MDMA ([@R354]) and a follow-up indicated robust fear reductions for up to 74 months \[([@R355]), see [Table 2A](#T4){ref-type="table"}\]. A caveat here is that it is unclear whether these effects of MDMA are solely attributable to its effects on DA, and not also to its effect on other targets of MDMA, notably 5-HT. Nonetheless, boosting DA transmission in conjunction with CBT could have significant potential translational value.

4.3. Noradrenergic system {#S8}
-------------------------

The noradrenergic system is crucial for both the formation and the maintenance of fear memories, as well as for extinction memories (reviewed in ([@R222]; [@R363])). Noradrenaline can enhance neuronal excitability in extinction-relevant brain regions such as the IL ([@R365]) and successful fear extinction is associated with enhanced extracellular levels of nor-adrenaline in the mPFC ([@R228]). Boosting noradrenaline levels, via administration of either noradrenaline itself ([@R343]) or of compounds such as yohimbine (see below) or methylphenidate ([@R2]) enhances fear extinction ([Table 3](#T5){ref-type="table"}). There is evidence from preclinical studies that activating β-adrenoceptors, one target receptor of noradrenaline, can also facilitate fear extinction ([Table 3](#T5){ref-type="table"}) \[for recent review, see ([@R141])\]. Conversely, depleting central noradrenaline or lesioning ascending noradrenaline projections from the locus coeruleus, impairs extinction, as does systemic alpha1 or β adrenoceptor blockade ([Table 3](#T5){ref-type="table"}) \[reviewed in ([@R363])\].

There has been interest in the clinical utility of targeting noradrenergic mechanisms to augment extinction. Here, we focus on α2-adrenoceptors given the recent clinical findings supporting the utility of α2-adrenoceptor antagonists in improving extinction. Based on results of rodent studies ([@R56]), two small clinical studies ([@R419]; [@R476]) have shown that combining yohimbine with CBT can reduce anxiety in patients with social anxiety disorder and claustrophobic fear ([Table 3A](#T6){ref-type="table"}). A third study found no CBT-augmenting benefit of yohimbine in patients with fear of flying; however, CBT may have exerted a 'ceiling effect' that occluded the drug\'s effect ([@R345]).

In rodents, blocking α2-adrenoceptors (e.g., with yohimbine) that function as autoreceptors on locus coeruleus neurons increases locus coeruleus activity and noradrenaline release in terminal regions ([@R471]). Yohimbine is anxiogenic and increases neuronal activity in widespread brain areas, including extinction-relevant areas such as the amygdala, mPFC and HPC ([@R472]). Downstream targets of yohimbine-induced noradrenaline release include β1-adrenoceptors, and increasing activity at these receptors in locus coeruleus terminal regions (mPFC) enhances extinction ([@R117]), possibly via facilitating extinction-relevant long-term potentiation ([@R154]) in a BDNF-dependent manner ([@R148]). Yohimbine facilitates extinction in rodents, including extinction-impaired subjects ([@R200], [@R200]), though a more selective α2-adrenoceptor, atipamezole, does not ([Table 3](#T5){ref-type="table"}) \[for further discussion, see ([@R222])\]. Yohimbine also protects against spontaneous fear recovery, in a manner similar to the effect of a noradrenaline uptake inhibitor, atomoxetine ([@R236]). However, yohimbine reduces fear only in the extinction context in which the drug was administered ([@R359]), which would be a limitation of the clinical goal of achieving context-independent reductions in fear. Thus, other strategies may be needed, including combination strategies where drugs which do produce context-independent extinction, for example targeting HDACs (see Section 4.10 Epigenetics), are combined with yohimbine.

4.4. Glutamatergic system {#S9}
-------------------------

Glutamatergic signaling plays a crucial role in synaptic plasticity and many forms of learning and memory, including fear extinction (see [Fig. 6](#F6){ref-type="fig"} for an overview). Fast excitatory glutamatergic signaling is mediated by ionotropic receptors (NMDA and AMPA), and slower signaling by metabotropic (mGluR1--8) receptors. Group I (mGluR1 and mGluR5) receptors are mainly expressed postsynaptically and coupled to Gq proteins enhancing phospholipase C (PLC) activity. Group II (mGluR2, mGluR3) and Group III (mGluR4, mGluR6--mGluR8) are both coupled to Gi proteins inhibiting adenylate cyclase (AC) activity and expressed on pre- as well as postsynaptic sites ([@R540]).

Pharmacological potentiation of AMPA receptor activation (by PEPA) facilitates extinction learning and retrieval ([@R549], [@R548]; [@R567]), although it is ineffective in severely extinction-impaired subjects ([@R536]). Studies using localized infusion of AMPA potentiators ([@R567]) and blockers ([@R130]; [@R353]; [@R565]) coupled with electrophysiological recordings suggest that AMPA-mediated effects on extinction are localized to the mPFC \[([@R567]) see [Table 4](#T7){ref-type="table"}, for recent detailed reviews ([@R48]; [@R367])\].

The part played in extinction by the metabotropic glutamate receptors mGluR1, mGluR5 and mGluR7 has also been evaluated. Antagonizing mGluR1 (which is expressed on ITC innervating neurons ([@R53]) with CPCCOEt ([@R248]) and antagonizing mGluR5 receptors in the IL ([@R460]) have been shown to impair extinction. Furthermore, gene mutations resulting in deficits in mGluR5 ([@R547]) or mGluR7 ([@R58]; [@R135]; [@R157]) impair extinction learning, while selective activation ([@R114]; [@R135]; [@R358]; [@R435]; [@R466]; [@R515]; [@R536]) improves extinction \[see [Table 4](#T7){ref-type="table"} for summary and ([@R48]; [@R367]) for more details\].

The most extensively studied glutamate receptor in relation to fear extinction is the NMDA receptor (NMDAR). As shown in [Table 4](#T7){ref-type="table"}, systemic or local administration of NMDAR antagonists into the BLA or mPFC produces extinction deficits \[reviewed in ([@R367])\]. Due to the potential for major side-effects (e.g. excitotoxicity) a general enhancement of NMDAR transmission is clinically undesirable and more subtle modulation of NMDAR signaling is required. NMDARs are specialized voltage-dependent, ligand-gated ion channels that are expressed as heterotetramers formed by GluN1 in combination with GluN2 or GluN3 subunits. To date, eight different splice variants of the GluN1 subunit, four distinctive GluN2 (GluN2~A--D~) subunits and two GluN3 (GluN3~A--B~) subunits have been identified \[for review see ([@R396])\]. Activation of NMDARs requires L-glutamate binding to GluNR2 subunits, L-glycine or D-serine binding to GluNR1 subunits and membrane depolarization relocating the channel pore-blocking Mg2+ and Zn2+ ions.

The repertoire of NMDAR subunits permits the assembly of a range of NMDARs with varying dissociable signaling properties. Systemic ([@R89]; [@R90]; [@R279]; [@R483]) or localized BLA ([@R277]; [@R483]; [@R484]) or mPFC ([@R277]; [@R484]) inhibition of GluN2~B~-containing NMDARs (via ifenprodil or Ro25--6981) disrupts extinction. Conversely, GluN2B overexpression enhances extinction ([@R504]). Recently, facilitated signaling of GluN2C/D-containing NMDARs in the BLA (via CIQ infusion) was also demonstrated to enhance extinction ([@R107]). The contribution of other subunits, such as GluN2A, remains to be determined.

The organization of NMDARs provides additional druggable pharmacological targets. GluN1 and GluN2 subunits are endowed with binding sites for positive and negative allosteric regulations that enable fine-tuning of NMDAR activity. The GluN1 subunit contains an inhibitory H+ binding site rendering GluN2B/D-containing NMDARs in particular sensitive to local pH changes, as well as to endogenous molecules with redox potential ([@R26]). The GluNR2 subunit is responsive to allosteric modification of NMDAR signaling by polyamines such as spermidine. Spermidine-induced activation of GluN2B signaling facilitates the consolidation of extinction ([@R160]; [@R176]), while arcaine, an antagonistic polyamine, disrupts extinction ([@R160]). A GluN2 allosteric binding site -- still uninvestigated in the field of fear extinction -- enables modulation of NMDAR signaling by neurosteroids (i.a. allopregnanolone) ([@R230]).

Nuanced pharmacological modulation of NMDARs can also be achieved by targeting the Zn2+ binding domain found on GluN2 subunits. Zn2+-binding to this modulatory site mainly inhibits GluN2A--containing NMDARs, by reducing NMDAR channel open probability ([@R395]). Brain Zn2+ signaling which, in addition to the NMDAR binding site, acts via other sites including the GPR39 Zn-sensing receptor ([@R224]), has been shown to exert both enhancing and attenuating effects on learning and memory via complex interactions with neurotransmitters and synaptic plasticity mechanisms (reviewed in [@R503]). Dietary Zn2+ supplementation impairs extinction ([@R425]), while dietary-induced reduction of brain Zn2+ levels rescues deficient extinction ([@R535]). Although these effects may be mediated by Zn2+ modulation of NMDAR signaling, other actions cannot be excluded (e.g., see discussion on HDAC inhibition in Section 4.10: *Epigenetics*). The same is true for another NMDAR-modulating ion, Mg2+, which has also been shown to facilitate extinction when globally enhanced in the brain ([@R4]; [@R348]).

The most extensively investigated allosteric modulation of NMDARs is mediated via the L-glycine binding site on the GluN1 subunit. As shown in [Table 4](#T7){ref-type="table"}, systemic administration of ligands on this binding site, D-serine or D-cycloserine (DCS), augments extinction consolidation \[see ([@R48]; [@R367]) for recent detailed reviews\]. There is evidence (although not consistent) that DCS may promote generalization of the extinction effect ([@R283]; [@R523]) that is, to other cues (e.g. odors, sounds, visual stimuli) that acquired fear during a more complex conditioning situation. Generalized extinction could be of potential clinical benefit, provided that cues that trigger adaptive reactions are not affected. However, DCS administration outside the consolidation window can limit the drug\'s effectiveness. When extinction or exposure sessions are too short or yield insufficient fear inhibition, DCS can strengthen (re-)consolidation of the original fear memory. Along these lines, the extinction augmenting effects of DCS require the subject to show at least some ability to extinguish ([@R36]; [@R41]; [@R200]; [@R477]; [@R513]; [@R529]; [@R536]). Finally, chronic DCS treatment leads to loss of effects on extinction, possibly via NMDAR desensitization ([@R402]; [@R421]). It is of note, that chronic treatment with antidepressants also disrupts the facilitating effects of DCS on extinction, possibly by interfering with NMDAR function ([@R533]).

Notwithstanding these caveats, DCS represents one of the best examples of translational research paving the way for novel anxiety treatments. DCS augmentation of CBT has been clinically studied in various anxiety disorders ([Table 4A](#T8){ref-type="table"}) including among pediatric patients \[see ([@R218]) for a recent review\]. To summarize the current clinical data, DCS-augmented CBT shows advantages in PTSD ([@R101]; [@R112]; [@R452]), specific phobia ([@R173]; [@R371]; [@R430]), SAD ([@R174]; [@R216]; [@R219]; [@R478]) and OCD \[([@R70]; [@R131]; [@R265]; [@R490]; [@R538]) but see ([@R324])\]. Panic disorder patients ([@R390]; [@R467]) also show faster symptom alleviation after DCS-augmented CBT. Reflecting the preclinical findings, negative outcomes were associated with short CBT sessions ([@R301]), insufficient within-session fear inhibition ([@R477]; [@R505]), chronic DCS treatment ([@R205]), DCS administration outside the therapeutic temporal window ([@R489]) and subclinical levels of fear \[([@R173]; [@R184]) but see ([@R264])\].

If these factors are properly attended to \[see above, reviewed in ([@R215])\], the evidence supports the adjunctive treatment of CBT with DCS for a range of anxiety disorders.

4.5. γ-Aminobutyric acid (GABA) {#S10}
-------------------------------

GABA is the main inhibitory neurotransmitter in the adult mammalian brain. Because extinction largely reflects the promotion of active inhibitory processes, it is not surprising that GABA serves as an important source of such inhibition. GABA signaling occurs largely via binding to ionotropic GABA~A~ and metabotropic GABA~B~ receptors (former GABAC receptors have been reclassified and are now termed GABA~A~ rho-subclass receptors). GABA~A~ receptors are pentameric, ligand-gated Cl^−^ channels which, upon activation induce hyperpolarization of cells and hence reduce neuronal excitability. Seven classes of GABA~A~ subunits (α~1--6~, β~1--3~, γ~1--3~, ρ~1--3,~ δ, ε, ) have been identified so far, permitting the assembly of highly variable GABA~A~ receptors with distinct functions and signaling properties. Furthermore, several allosteric binding sites, in addition to the GABA binding pocket located at the α/β-subunit interface, allow nuanced modifications of GABA~A~ receptor signaling. The allosteric benzodiazepine (BZD) binding site is localized at the interface of α-and -γ-subunits and when activated, facilitates GABAergic transmission by promoting GABA binding to the receptor and increasing the opening probability of the Cl^−^ channel. The binding sites of other allosteric modulators of GABA~A~ signaling including barbiturates and neurosteroids among others are not yet fully characterized \[see [Fig. 7](#F7){ref-type="fig"} and ([@R179]; [@R313])\].

In preclinical studies, the robust inhibitory effect of full GABA~A~ receptor agonists at the GABA binding site (α/β-subunit interface) (e.g. muscimol), is often used to inactivate a brain region to clarify its participation in certain functions including extinction. Muscimol-injections into the BLA ([@R277]; [@R276]; [@R468]), mPFC/IL ([@R277], [@R278]; [@R468]) and HPC \[([@R86]; [@R468]), see [Table 5](#T9){ref-type="table"} for a summary\] disrupt extinction learning and memory, supporting the crucial involvement of these areas. However, muscimol infusion into the BLA and IL facilitates extinction in some studies ([@R7]).

There is solid evidence that fear extinction learning is associated with upregulation of GABAergic markers in the AMY, underscoring the importance of a certain level of GABAergic signaling in this brain area for the successful formation of extinction memories. For example, levels of gephyrin, a clustering protein facilitating postsynaptic scaffolding of GABA~A~ receptors, were enhanced 2 h following extinction training along with enhanced surface expression of GABA~A~ receptors in the BLA ([@R73]). Extinction learning also increases GABA~A~ receptor α~2~- and β~2~ subunit mRNA and levels of the GABA-synthesizing enzyme glutamate decarboxylase (GAD) and the GABA transporter GAT1 ([@R203]). Further demonstrating the importance of GABAergic signaling to extinction, fear extinction learning is disrupted by mutation-induced deficits in the activity-dependent GAD isoform GAD65 ([@R449]), and by viral knock-down of the constitutive GAD isoform GAD67 ([@R202]). While these findings suggest that upregulation of GABAergic signaling supports extinction, GABA~A~ receptor antagonists such as picrotoxin or bicuculline can enhance extinction memories when administered systemically ([@R330]), or when infused into the BLA ([@R30]) or specific (fear promoting) areas (PL)of the mPFC ([@R142]; [@R510]). The reason for these apparent contradictions is not yet clear.

Preliminary findings from studies using genetically modified mice suggest that the development of subunit-selective GABA~A~ receptor drugs could be a promising way to more distinctly utilize GABAergic mechanisms facilitating extinction. For example, there is reduced mRNA expression of α5 and γ1 subunits in the AMY of a mouse model of enhanced anxiety ([@R506]) displaying impaired extinction ([@R559]). In addition, deletion of α~5~-containing GABA~A~ receptors in the HPC is sufficient to impair fear extinction recall ([@R556]) while global deletion of the GABA~A~α~3~ subunit produces modest improvements in extinction learning ([@R137]).

An additional possible explanation for some paradoxical findings concerning GABA regulation and AMY function in extinction is the fact that most of the prior studies have performed pharmacological or genetic manipulations that affect either the entire brain, just the AMY, or even only AMY subregions. Despite this, we now know that GABA receptors are found on most of the neuronal cell types and thus even a subregion-specific manipulation is likely to affect many different cell populations which may have opposing functional effects. One recent attempt to address this complexity involved the use of an inducible GABAa1 knockout strategy limited only to the corticotropin-releasing-hormone containing neuronal population ([@R149])), which revealed relatively specific effects, including enhanced anxiety and extinction deficits. It is likely that future studies aimed at cell-type specific manipulations will help address the vast complexity of the many different cell types combined with the large number of different GABA receptor populations.

As mentioned above, the multiple different binding sites found with-in GABA~A~ receptors can be used to elicit a more nuanced modulation of GABA~A~ receptor activity. Positive allosteric modulation of GABA~A~ receptor activity via BZD, represents the most widely described drug-based strategy for acute treatment of anxiety states ([@R310]). The prevalence of BZD use among patients suffering from mental disorders is high, and is estimated to range between 40 and 70% of these patients ([@R82]) However anxiolytic treatment with BZDs is recommended only for short periods of time, due to several disadvantages including its sedative effects, the development of dependence and difficulties with discontinuing chronic treatment ([@R387]). The sedating and calming effects of BZDs might in fact interfere with extinction possibly via reduced arousal and decreased release of neurochemicals (e.g. noradrenaline) and stress hormones (e.g. glucocorticoids) that support extinction \[([@R29]), see Section 4.8 *Glucocorticoids*) for details\]. BZDs may also render extinction memories dependent on the drug-induced internal anxiolytic-state (state dependent learning), which upon BZD discontinuation may no longer be accessible. These concerns are borne out by preclinical data showing that systemic ([@R40]; [@R54]; [@R159]; [@R191], [@R192], [@R193]; [@R407]) or intra-BLA ([@R191], [@R192]) BZD administration impairs extinction ([Table 5](#T9){ref-type="table"}), presumably also through state-dependent mechanisms. Systemic treatment with a BZD inverse agonist ([@R189]; [@R249], [@R250]) has similar effects (see [Table 5](#T9){ref-type="table"} for a summary\]. Hence, combining BZD with CBT needs careful consideration. As well as further development of BZDs targeting specific subunits of the GABA~A~ receptor \[reviewed in ([@R170])\], which provides some hope, there is preliminary evidence that putative novel anxiolytics that do not impair extinction learning \[e.g. neuropeptide S; ([@R474]) see Section 4.7 *Neuropeptides*\] can be developed to help reduce patients\' aversion to the unpleasant and demanding procedure of recalling details of their traumatic memories, thus increasing their willingness to interact with the psychotherapist.

In contrast to the relatively large number of studies of the GABA~A~ receptor, only a few studies have investigated the role of GABA~B~ receptors. Functional GABA~B~ receptors are heterodimers containing a GABA~B1~ and a GABA~B2~ subunit; the GABA~B1~ subunit has two isoforms -- GABA~B1a~ and GABA~B1b~ ([@R145]). While functional deletion of GABA~B~ receptors (GABA~B1a/b~ knock-out) impairs extinction learning ([@R235]), pharmacological GABA~B~ receptor antagonism does not ([@R199]; [@R499]). Systemic administration of (non-selective) agonists or positive allosteric modulators of GABA~B~ signaling also has inconsistent effects (impairing or negative) on extinction \[([@R199]; [@R499]) see [Table 5](#T9){ref-type="table"}\]. A final answer to this question regarding the role of GABA~B~ receptors may have to await the availability of GABA~B1a~-and GABA~B1b~-selective compounds

Taken together, the available evidence indicates that GABA signaling has a major, but spatially and temporally restricted role in the formation of fear extinction memories. While GABA that is engaged during extinction is likely to support synaptic plasticity, increasing GABAergic tone globally seems to limit the efficacy of extinction-based therapies by mechanisms outlined above. Therefore, it is unlikely that drugs broadly targeting the GABA system will be useful in this respect. Pharmacological adjuncts to exposure therapy targeting the GABA system would rather need to strike a balance between driving and maintaining relevant GABA activity without over-activating the system. The evidence so far suggests that subunit-selective or allosteric (distinct from BZD) modulation of GABA~A~ receptor signaling may hold promise in this regard.

4.6. Cannabinoids {#S11}
-----------------

A growing body of literature demonstrates that the endogenous cannabinoid (eCB) system modulates neuronal excitability in stressful and fearful situations ([@R99]; [@R177]). eCB signaling has been implicated in emotional and cognitive processing of threatening stimuli, for instance during the consolidation of fear and fear extinction memories (for more detailed recent reviews see ([@R434]; [@R178]). Upon neuronal activation, an eCB (anandamide) and 2-arachidonoylglycerol ([Fig. 8](#F8){ref-type="fig"}) are rapidly synthesized in the postsynaptic neuron (within minutes) and released into the synaptic cleft to modulate presynaptic signaling by the activation of G~i/0~-coupled CB-1 receptors (CB-2 receptors are mainly expressed on immune cells, osteoblasts, osteoclasts and hematopoietic cells but also on neuroglia).

Supporting a role of eCB signaling in the extinction of aversive memories (see [Fig. 8](#F8){ref-type="fig"} for overview), there are increased eCB levels in the mouse BLA following extinction training ([@R322]). Conversely, PTSD patients show low brain anandamide levels ([@R374]). In rodents, facilitation of eCB signaling by CB-1 receptor agonists or exogenous cannabinoids \[cannabidiol, ([@R33])\], reuptake inhibitors \[AM404, ([@R33]; [@R75]; [@R393])\] or anandamide degradation blockers \[AM3506, URB 597, ([@R178])\] enhances the formation or consolidation of extinction memories. Blockade or knock-out of CB1-receptors ([@R63]; [@R242]; [@R322]; [@R377]; [@R394]; [@R415]; [@R427]; [@R509]) impairs extinction and blocks the pro-extinction effects of drugs that facilitate eCB transmission ([@R75]; [@R113]; [@R178]) (see [Table 6](#T10){ref-type="table"}). Collectively, these observations point to CB-1 receptor mediated eCB signaling as a powerful modulator of extinction.

Following up on these studies, intra-cerebral infusions of CB1-receptor agonists and antagonists have revealed a potential role of mPFC-BLA eCB signaling in extinction \[see [Table 6](#T10){ref-type="table"}, ([@R113]; [@R151]; [@R178])\]. CB1-receptor activation inhibits both presynaptic glutamate and GABA release. The release of anandamide and concomitant CB1-receptor activation induce long-term depression of inhibitory transmission (LTDi) in the BLA ([@R17]; [@R178]). In addition, a recent study demonstrated that enhanced inhibitory input via activation of CB1 receptor expressing cholecystokinin (CCK) positive interneurons selectively reduces firing of BLA fear neurons and promotes extinction ([@R517]). Of note is the fact that it has also been shown that one potential mechanism for the CB1 effect on extinction within the AMY is via blockade of CCK release, as an intra-AMY CCK antagonist reversed the extinction blockade of systemic CB1 antagonists, and CCK agonists block extinction ([@R74]).

In summary, current preclinical data suggest that eCB signaling gates BLA function through plastic changes, including a long-lasting depression of inhibition, to modulate extinction-related AMY activity. Initial results from clinical studies in healthy volunteers suggest that exogenous cannabinoid administration strengthens extinction and protects against reinstatement \[see [Table 6A](#T11){ref-type="table"}, ([@R91]; [@R424])\]. Future clinical trials in extinction-impaired PTSD patients will be needed to show whether cannabinoids (or substances which increase endogenous eCB signaling, such as FAAH inhibitors) might prove useful as adjuncts to CBT-based therapy.

4.7. Neuropeptides (oxytocin, neuropeptide Y, neuropeptide S, opioids) {#S12}
----------------------------------------------------------------------

Various neuropeptides and their corresponding receptors are localized in brain regions mediating emotional behavior and stress response and have been considered as potential anxiolytic drug targets ([@R42]; [@R123]; [@R170]). While other neuroptides such as hypocretin/Orexin ([@R143]) may also be involved in fear extinction, we will here address the role of oxytocin, neuropeptide Y, neuropeptide S and opioids in extinction.

### 4.7.1. Oxytocin {#S13}

The oxytocin (OXT) system, strongly implicated in social cognition and behavior, is posited to play a role in anxiety disorders with impaired social functioning ([@R346]; [@R373]). OXT is synthesized in the paraventricular (PVN) and supraoptic nuclei of the hypothalamus and processed along the axonal projections to the posterior pituitary gland. Upon neuronal activation OXT is released from secretory vesicles into the peripheral circulation as neurohypophyseal hormone. The central nervous system (CNS) component of OXT is derived from dendritic release of the same cell population ([@R307]), as well as from the OXT-synthesizing parvocellular PVN cells sending projections throughout the brain \[reviewed in ([@R155])\]. OXT receptors are typically G~q~-protein coupled and have potential allosteric binding sites for Mg^2+^ and steroids like cholesterol. The distribution of OXT receptors has not been fully delineated, but OXT fibers and neurosecretory nerve endings have been described in, among other regions, the AMY \[especially CeL ([@R255]; [@R521])\], the dorsal and ventral HPC and the main monoamine nuclei -- substantia nigra (dopamine), raphe nuclei (serotonin) and the locus coeruleus (noradrenaline) \[see ([@R155]) for review).

Regulatory effects of OXT on stress-induced activation of the hypothalamic--pituitary--adrenal (HPA) axis, as well as direct OXT effects on the brain and specific parts of the extinction circuitry, can affect fear extinction in various ways. Intracerebroventricular (icv) infusion of OXT prior to fear conditioning does not affect fear learning but facilitates later extinction acquisition and retrieval ([@R514]). Conversely, OXT receptor antagonists impair extinction learning and retrieval when administered icv prior to fear acquisition ([@R514]). More localized OXY infusions into the central CeA reduce fear expression by inhibiting CeM excitatory output to fear-eliciting brainstem structures ([@R227]) ([@R525]), suggesting one possible mechanism for the effects of icv OXY on extinction.

Another potential mechanism might be OXT-induced dampening of stress-induced activation of the HPA axis ([@R103]; [@R201]; [@R423]; [@R541]). As explained in more detail in Section 4.8 *Glucocorticoids*, glucocorticoid release during an actual learning process facilitates cognitive processing \[reviewed in ([@R29])\], hence the release of endogenous OXT during traumatic experiences ([@R566]) may interfere with the consolidation of fear memories. Along these lines, OXT-mediated reduction of HPA axis activity and subsequent lower glucocorticoid levels could interfere with fear acquisition, resulting in a weaker fear memory that is more susceptible to extinction training. In this context, OXT administration either icv or intra BLA prior to extinction training disrupts extinction learning \[([@R514]) ([@R270]) see [Table 7](#T12){ref-type="table"} for summary\]. OXT infusions into the dorsolateral septum prior to extinction training have the opposite effect and facilitate extinction learning and retrieval in a social fear conditioning paradigm that may recruit a somewhat different neural circuitry than non-social forms of fear ([@R566]).

Considering that systemically applied neuropeptides do not cross the blood--brain-barrier, clinical use of neuropeptides would require a direct pathway to the human brain. In the case of OXT, this may be feasible via intranasal administration ([@R38]). Intranasal OXT administration has been demonstrated to reduce stress-induced cortisol release in humans ([@R103]; [@R201]; [@R423]), and to attenuate AMY hyperactivity as well as AMY-hindbrain coupling in anxiety patients \[([@R252]; [@R267])\]. In a recent study investigating the effects of intranasal OXT treatment on fear extinction in healthy volunteers, OXT increased initial fear expression during extinction training, but this effect was gone by the end of training and there was a lower level of fear in the OXT treated group in extinction retrieval ([@R5]). These data raise the prospect of OXT-augmented CBT effectiveness.

### 4.7.2. Neuropeptide Y {#S14}

Neuropeptide Y (NPY) contains 36 amino acids and is the most widely expressed neuropeptide in the mammalian brain. There are particularly high concentrations of NPY in the limbic system, including in the AMY, the HPC and the periaqueductal gray. Six G-protein coupled NPY receptors (Y1--6) have been identified, among which Y1, Y2, Y4, and Y5 mediate central effects. Y1 mRNA is present at a high level in brain areas involved in memory processing, namely the AMY, HPC, thalamus, hypothalamus, and the cerebral cortex. The AMY, HPC, and hypothalamus are also rich in Y2 receptors, while Y5 receptors can be detected in HPC, cingulate cortex and thalamic and hypothalamic nuclei ([@R401]) \[reviewed in ([@R221])\].

Icv administration of NPY facilitates extinction learning ([@R183]), while genetic deletion of NPY disrupts extinction acquisition and subsequent retrieval ([@R522]). Extinction deficits caused by NPY knock-out are rescued by AAV-mediated NPY re-expression in the BLA ([@R522]), where NPY co-localizes with GABAergic neurons modifying inhibitory control of BLA projection neurons ([@R328]). To elucidate which NPY receptors mediate the BLA-associated effects on extinction, the consequences of gene deletion via either deletion of Y1 or Y2 receptors or double Y1/Y2 deletion have been examined. Deletion of Y1 receptors impaired extinction learning, while Y2 receptor deletion had no effect ([@R522]). Underscoring the importance to extinction of Y1 receptors in the BLA, local infusion of the Y1 agonist Leu31Pro34-NPY prior to extinction training led to stronger extinction retrieval ([@R183]; [@R268]). Further studies are required to further delineate the underlying mechanisms of Y1-mediated facilitation of extinction, and to investigate the potential clinical use of NPY and Y1 receptor agonism as adjunctive therapy to CBT.

### 4.7.3. Neuropeptide S {#S15}

Neuropeptide S (NPS) is synthesized in neurons located adjacent to the locus coeruleus ([@R546]) and binds to G-protein coupled NPS receptors expressed in the BLA among other areas. Intra-BLA infusion of exogenous NPS accelerates extinction learning, while BLA NPS receptor antagonism (via SHA68) impairs extinction learning and retrieval and increases fear renewal ([@R71]; [@R240]) ([Table 7](#T12){ref-type="table"}). NPS treatment also rescues deficient extinction learning in hyperanxious rats ([@R474]), exhibiting aberrant cortico-AMY activation ([@R366]). The activation of NPS receptors in the BLA increases excitatory input to GABAergic ITCs, thus increasing feed-forward inhibition to CeM neurons and reducing fear expression ([@R340]; [@R341]; [@R398]). Exogenous NPS administration is also associated with enhanced DA release in the mPFC ([@R465]), suggesting another mechanism for strengthening extinction (see Section 4.2 *Dopaminergic system*).

Underscoring the translational relevance of NPS, healthy human volunteers carrying the NPS receptor polymorphism rs324981, which potentiates NPS efficacy at the receptor, show enhanced extinction in a virtual reality fear potentiated startle paradigm ([@R156]). Additional studies are required to assess whether increasing NPS signaling improves extinction in anxiety patients. This would be aided by the development of small molecule NPS receptor agonists.

### 4.7.4. Opioids {#S16}

The opioid peptide family comprises different members including endorphins, enkephalins, dynorphins and hemorphins. The 3 classical opioid receptors \[µ (MOR), κ (KOR) and δ (DOR)\] show heterogeneous expression throughout the brain and are located in extinction-relevant brain areas including the AMY, mPFC and HPC. Typically, MOR, KOR and DORs are coupled to G~i~-proteins, reducing (in most cases) net neuronal excitability and reducing neurotransmitter release upon activation \[reviewed in ([@R381])\].

There is evidence that morphine application (intended for pain management) following an acute trauma attenuates the incidence of PTSD at later timepoints ([@R46]; [@R220]; [@R342]; [@R501]). Aside from this potential PTSD preventing property of opioids, several studies have tried to determine the importance of opioids in extinction.

Systemic administration of the opioid receptor antagonist naloxone (which has highest affinity to MOR, but also inhibits KOR and DOR) impairs extinction when given prior to extinction training ([@R338]; [@R337]) but not when applied after extinction training or prior to retrieval, see [Table 7](#T12){ref-type="table"}). Subsequent investigations have demonstrated that extinction-impairing effects are mediated by MORs in the PAG \[as shown with the selective MOR antagonist CTAP in the PAG ([@R335]; [@R403])\].

The AMY ITCs express high levels of MOR ([@R53]), and lesioning of MOR-expressing neurons in the ITCs following extinction training impairs extinction retrieval ([@R295]), indicating that MOR signaling in the ITCs contributes to extinction consolidates. Probably due to the high addiction potential of MOR agonists, no clinical studies have investigated their potential in CBT. However, treatment with the opioid receptor antagonist naloxone prior to exposure therapy is associated with reduced treatment success ([@R15]; [@R125]), which is in accordance with preclinical results ([Table 7](#T12){ref-type="table"}).

Another opioid receptor gaining attention in the field of fear extinction is the KOR, activated by endogenous dynorphins (reviewed in [@R458]). Human volunteers with single nucleotide polymorphisms in the prodynorphin gene showed increased skin conductance (a physiological measure of fear) during fear extinction training and blunted functional connectivity between AMY and mPFC ([@R31]). Along these lines, genetic deletion of dynorphin or systemic antagonism of KORs in rodents impairs extinction learning and reduces neuronal activity in the BLA and mPFC ([@R31]). In contrast to these extinction-impairing effects, systemic administration of KOR antagonists protects against fear renewal ([@R84]) -- an effect mimicked by local infusions into the ventral HPC ([@R85]). Additional studies will help clarify these effects and their possible relevance to clinical use of opioidergic drugs in conjunction with exposure-based therapies.

4.8. Glucocorticoids {#S17}
--------------------

Emotionally arousing experiences activate the HPA axis and the release of glucocorticoids (GCs) into the bloodstream. GCs which include cortisol in humans, and corticosterone in rodents are lipophilic and readily cross the blood--brain-barrier to interact with glucocorticoid (GR) and mineralocorticoid receptors (MR) in the brain. GRs are widely expressed throughout the brain including the AMY, HPC and PFC ([@R29]). Early pioneering studies reported that extinction-memory formation is disrupted by adrenalectomy ([@R469]), as well as, more recently, by compounds that antagonize GRs, such as mifepristone ([@R551]), or that inhibit corticosterone synthesis \[metapyrone, ([@R27]; [@R35]; [@R190]; [@R551], [@R552])\] (see [Table 8](#T13){ref-type="table"}). Conversely, systemic administration of corticosterone ([@R35]) or the GR agonists dexamethasone or RU28362 ([@R376]; [@R551], [@R552]) facilitate the consolidation of aversive and appetitive extinction memories (see [Table 8](#T13){ref-type="table"}).

How can stress hormones promote the formation of extinction memories? Cytosolic GRs induce genomic responses by binding to glucocorticoid responsive elements within promoter regions of GC-responsive genes, and act as transcription factors inducing the expression of learning-related genes. In addition, membrane-bound GRs can induce non-genomic actions of relevance to extinction, including the synthesis of eCBs (see Section 4.6 *Cannabinoids*) from membrane phospholipids ([@R111]; [@R211], [@R212]). Further supporting a link between GRs and eCBs, and possibly of importance in GC-augmented extinction consolidation, adrenalectomy leads to reduced CB-1 receptor expression ([@R311]) and GC-mediated memory consolidation is prevented by CB-1 receptor antagonists ([@R62]).

GRs can also induce indirect learning-relevant genomic actions via activation of intracellular signaling cascades such as the ERK/MAPK pathway (reviewed in [@R431]) in cooperation with other neuro-transmitter systems or ion channels including β-adrenoceptors ([@R441]), and L-type calcium channels ([@R244]). These interrelated effects are functionally relevant, given that the infusion of β-adrenoceptor antagonists into the BLA blocks the memory-facilitating effects of systemically administered glucocorticoids ([@R422]; [@R440]).

Another important functional interaction occurs between GCs and the glutamate system. GCs potentiate glutamatergic signaling via genomic and non-genomic mechanisms, by (i) increasing the readily releasable pool of presynaptic glutamate vesicles, and (ii) enhancing NMDA and AMPA receptor surface expression through increased receptor trafficking (reviewed in [@R417]). The concomitant activation of GC and NMDA receptors, which can occur during emotionally arousing experiences, induces downstream nuclear mechanisms that result in histone modifications (reviewed in [@R431]), an epigenetic mechanism implicated in extinction (see Section 4.10: Epigenetics for details). Underscoring the potential importance of emotional arousal and thus of GC release in this process, pretreatment with the anxiolytic BZD lorazepam (resulting in reduced arousal in response to the stressor) blocked epigenetic modifications on Histone H3, while application of the anxiogenic BZD inverse agonist FG7142 ([@R472]) induced transcription facilitating acetylation and phosphorylation on histone tails ([@R397]). These epigenetic effects could contribute to the aforementioned extinction impairing effects of BZDs (see Section 4.5: γ-*Aminobutyric acid* (GABA) and [Table 5](#T9){ref-type="table"}).

In contrast to the effects of acute GC elevations, chronic high levels of corticosterone reduce cell-surface NMDA and AMPA receptor expression ([@R162]). This loss of critical plasticity mechanisms might be one explanation as to why anxiety patients with a history of repeated traumatic events, such as combat veterans, show greater resistance to treatment. However, a considerable proportion of PTSD patients have reduced cortisol levels ([@R557]) and small case studies suggest that there are beneficial effects of CBT and adjunctive cortisol administration in PTSD patients ([@R558]). A number of larger studies are under way to extend this work (NCT01108146, NCT00751855, NCT01525680). In addition, it has been found that cortisol-augmented CBT has efficacy in acrophobia ([@R104]), arachnophobia ([@R481], [@R482]) and social phobia \[([@R481]) see [Table 8A](#T14){ref-type="table"} for a summary\]. Whether cortisol augmented CBT for non-phobic anxiety disorders, including also GAD, facilitates fear inhibition is currently being investigated in ongoing clinical studies (see [@R57]). Furthermore, future studies may implement more selective GC agonists than cortisol (which is also acting on MRs) to avoid nonspecific side effects.

4.9. Neurotrophins and miscellaneous targets {#S18}
--------------------------------------------

### 4.9.1. Fibroblast growth factor-2 {#S19}

Fibroblast growth factor-2 (FGF2) is a multi-functional growth factor involved in brain development and learning-related molecular signaling cascades (reviewed in [@R167]). FGF2 signaling is associated with glutamate-mediated synaptic plasticity ([@R380]), L-type voltage gated calcium channel expression and activation ([@R464]) and phosphorylation of both MAPK ([@R1]) and CREB ([@R495]). FGF2 also promotes LTP in the HPC ([@R508]). Hence, FGF2 interacts with the molecular tools required for the formation and consolidation of extinction memories. FGF receptors are tyrosine kinase receptors expressed widely throughout the brain, including in areas within the extinction circuitry such as the HPC and the CeA, and FGF2 expression in the HPC and the mPFC is induced under stress ([@R356]), thus suggesting that emotionally arousing situations requiring new learning generate increased FGF2 signaling which supports the formation of emotional memories.

FGF2 has been shown to cross the blood--brain barrier ([@R106]) and pioneering work demonstrates that systemic administration of FGF2 prior to or following extinction training facilitates the consolidation of extinction memories ([@R165], [@R166]). Local infusion into the BLA replicates the extinction-facilitating effects of systemic FGF2 ([Table 9](#T15){ref-type="table"}), demonstrating at least one key site of this neurotrophin\'s action ([@R168]). Of significant importance, is the fact that FGF2-augmented extinction has been associated with enhanced protection against return of fear phenomena including renewal and reinstatement \[([@R165], [@R166], [@R168]), see [Table 9](#T15){ref-type="table"} for details\] making it an interesting candidate for future clinical applications. Clinical studies investigating the potential of FGF2 in CBT could be implemented in the near future as human trials investigating FGF2 for angiogenesis have already shown some drugs to be safe ([@R269]).

### 4.9.2. Brain-derived neurotrophic factor {#S20}

Brain-derived neurotrophic factor (BDNF) is the most abundant neurotrophin in the CNS and a key player in synaptic plasticity (reviewed in [@R14]). BDNF binds with high affinity to the tropomyosin-related kinase B (TrkB) receptor and with low affinity to the p75^NTR^, a receptor for multiple neurotrophins ([@R428]). BDNF and TrkB are present in the HPC, AMY, PFC and the hypo-thalamus, and are integral components of fear extinction mechanisms as blunted activity of BDNF-TrkB signaling is associated with deficient extinction retrieval in rats ([@R241]). Conversely, increased levels of BDNF mRNA are observed in the BLA ([@R76]), mPFC ([@R45]) following successful fear extinction. The potential utility of BDNF-TrkB signaling as cognitive enhancing target is underscored by the findings that stimulating TrkB signaling by administering the TrkB agonist 7,8-dihydroxyflavone (DHF) facilitates LTP induction in the AMY ([@R292]) and can augment fear extinction ([@R410]; [@R442]).

Haploinsufficiency of BDNF leads to deficits in extinction learning and retrieval ([@R420]), while inhibition of the BDNF-evoked signaling cascade via transfection of a dominant negative form of the TrkB receptor specifically disrupts extinction consolidation in a fear potentiated startle paradigm ([@R76]). Conversely, systemic injection of the TrkB agonist DHF promoted extinction in a stress model of impaired fear extinction and protected against the reinstatement of fear ([@R13]) (for an overview, see [Table 9](#T15){ref-type="table"}). In mice and humans, a single nucleotide polymorphism (SNP) in the BDNF gene (Val66Met), causing inefficient BDNF trafficking and reduced activity-dependent BDNF secretion, is associated with poor extinction ([Table 9](#T15){ref-type="table"}) and abnormal fronto-AMY activity ([@R480]). Moreover, human carriers of the BDNF Val66Met SNP show reduced responsivity to exposure-based therapies \[reviewed in ([@R331])\], underscoring the potential role of BDNF in deficient fear extinction.

Studies aimed at identifying the site of BDNF-induced effects on extinction showed that deletion of BDNF in the HPC, but not in the PL([@R77]), impairs fear extinction learning ([@R204]). In addition, injection of BDNF antibodies (anti-BDNF) in the IL prior to extinction training disrupts acquisition and retrieval of extinction memories while anti-BDNF infusions in the PL cortex do not affect extinction ([@R442]) ([Table 9](#T15){ref-type="table"}). These findings indicate that BDNF signaling in the HPC and the IL support the formation and maintenance of fear extinction memories. In fact, local BDNF injections in the IL produced fear inhibition for recent as well as remote fear memories even in the absence of extinction training ([@R410]; [@R442]). Given the possibility that BDNF infusions into the IL could reinstate fear by using the aforementioned extinction-independent paradigm ([@R410]), BDNF seems to induce signaling cascades crucial for the formation of extinction memories rather than decreasing the stability of the original fear memory. Overall these effects are consistent with a model in which the effects of BDNF are brain-region dependent, and BDNF appears to enhance synaptic plasticity of the most robust form of learning occurring in a time- and region-dependent manner.

Various targets described in this review may mediate their effects on extinction via interactions with BDNF. For example, chronic treatment with the SSRI fluoxetine (Section 4.1: *Serotonergic system*) facilitates extinction and enhances BDNF levels in the AMY and the HPC ([@R243]). Valproate, an extinction-promoting inhibitor of histone deacetylation (see Section 4.10: *Epigenetics*), increases BDNF mRNA in the mPFC ([@R45]). Furthermore, TrkB activation triggers the release of eCBs ([@R290]) and increases the expression of CB1 receptors ([@R312]), hence potentially contributing to extinction memory formation (see Section 4.6: *Cannabinoids*). Finally, BDNF Met66 knock-in mice exhibit dysfunctional NMDA receptor-dependent synaptic plasticity in addition to reduced extinction acquisition ([@R375]) that is rescued by systemic administration of D-cycloserine ([@R561]), underscoring an additional strong interaction between BDNF and the glutamatergic system \[see ([@R14]) for more details\].

These findings suggest that BDNF signaling may be an important common signaling pathway for various systems involved in extinction. Although poor blood--brain-barrier permeability ([@R545]) limits the therapeutic potential of BDNF itself, TrkB receptor agonists such as DHF (see above) or LM22A-4 ([@R323]) may hold promise for CBT-adjunctive therapy in anxiety.

### 4.9.3. Nitric oxide and methylene blue {#S21}

Nitric oxide (NO) signaling has received considerable attention in terms of its effect on fear learning and has been shown, for example, to be implicated in the formation of LTP at thalamic input synapses in the LA ([@R463]). One recent study did demonstrate that reducing NO signaling via inhibition of nitric oxide synthase (e.g. via L-NAME) impairs extinction learning and retrieval ([@R308]), indicating that NO signaling may also be involved in the formation and maintenance of fear extinction memories.

More work has been done on the brain penetrant methylene blue, which is an inhibitor of NO synthase, as well as a central monoamine oxidase (MAO) inhibitor and a cerebral metabolic enhancer (reviewed in [@R439]). A contribution of nitric oxide to the behavioral effects of this and related compounds was suggested in relation to their observed antidepressant-like activity ([@R195]).

In rodents, subchronic administration of methylene blue facilitates extinction retrieval ([@R161]) ([Table 9](#T15){ref-type="table"}) and increases metabolic activity in the IL subdivision of the mPFC. Methylene blue administration also rendered extinction memories resistant to fear renewal when administered following extinction training in a learned helplessness model exhibiting impaired extinction ([@R544]).). Because methylene blue is used to treat metemoglobinemia and has a well-described safety profile ([@R384]), these preclinical data could be quickly moved forward to clinical investigations. Indeed, the first clinical study has recently reported that methylene blue treatment during CBT led to greater fear inhibition that was persistent for at least one month \[([@R507]) see [Table 9](#T15){ref-type="table"} A for details\]. However, similar to the profile of DCS discussed earlier, only those patients capable of showing some extinction benefited from the methylene blue treatment. A clinical trial investigating the potential of methylene blue in PTSD (NCT01188694) is now under way.

### 4.9.4. Histamine {#S22}

The tuberomammillary nucleus is the main source of histamine in the brain. Histaminergic projections innervate main monoaminergic nuclei, such as raphe nuclei and locus coeruleus ([@R286]), as well as extinction relevant brain areas, including the AMY, mPFC and hippocampus ([@R256]). To date, 4 histamine receptor subtypes (H1--4) have been identified -- H1--3 are expressed in the CNS, while H4 is involved in chemotactic processes of the immune system. Local histamine infusions into the CA1 region of the HPC have been associated with improved extinction consolidation ([@R37]). This effect is H2 receptor mediated, since the H2 agonist dimaprit facilitates extinction consolidation while the histamine H2 antagonist ranitidine impairs it, when injected into the CA1, BLA or IL following extinction training ([@R37]; [@R138]). Furthermore, both histamine and the H2 agonist dimaprit facilitate extinction-induced phosphorylation of Erk1, suggesting a possible molecular pathway mediating the augmenting effects of H2 receptor agonism on extinction consolidation ([@R37]). However, although the H1 antagonist hydroxyzine has been used in some anxiety therapies ([@R171]), the potential clinical use of histaminergic drugs in particular targeting the H2 receptor for CBT augmentation has not been investigated.

### 4.9.5. Voltage gated calcium channels {#S23}

Voltage-gated calcium channels (VGCCs) are classified into L-, P/Q-, R-, N- and T-type VGCCs (for a review see [@R66]). A rise in intracellular calcium via NMDA receptor or VGCC activation initiates various second messenger signaling cascades that play a role in LTP formation. Due to their neuronal expression as well as their association with gene transcription the L-type calcium channels (LTCCs) Cav1.2 and Cav1.3 ([@R492], [@R493]) have attracted most attention in the fear conditioning field.

Early studies have shown that systemic injections of LTCC blockers, e.g. nifedipine (that inhibits Cav1.2 and Cav1.3 channels), impair fear extinction acquisition ([@R55]). However, whole-brain gene knockout of Cav1.3 channels ([@R52]; [@R332]) as well as conditional knockout of Cav1.2 on CaMKII-expressing principal neurons ([@R334]) failed to replicate deleterious effects of LTCC blockers on extinction training. Pre-training icv infusion of nifedipine has revealed no effect on extinction learning ([@R52]), suggesting that the extinction-impairing effects of systemic nifedipine may be due to peripheral actions ([@R527]).

However, pre-training intra-BLA or intra-HPC infusion of nifedipine, or of another LTCC blocker, verapamil, impairs extinction retrieval 24h later ([@R93]; [@R100]), indicating a role for LTCCs within these regions in the consolidation of extinction. This effect could be related to Cav1.3 mediation of synaptic plasticity and neuronal excitability in the AMY ([@R333]) or to altered neuronal firing in the CA1 region of the HPC ([@R150]). However, the effect on extinction consolidation of selective Cav1.3 activation has not been assessed so far.

While activation of Cav1.2 channels produces severe neurological effects and germline gain of Cav1.3 function is deleterious ([@R456]), selective Cav1.3 activation in adulthood has been shown to be tolerated at least in mice ([@R209]; [@R473]). Hence, short term use of such compounds, as would typically be required in combination with exposure therapy, should be possible. Taken together, these preclinical findings raise the prospect of targeting LTCCs, and Cav1.3 in particular, for the treatment of anxiety.

4.10. Epigenetics {#S24}
-----------------

The formation of extinction memories requires an intricate regulatory network of signal transduction, gene transcription and translation. A key step in this process involves the coordinated transcription of specific genes coding for learning-associated transcription factors, synaptic plasticity factors, neurotransmitter receptors, cytoskeletal proteins and other cellular substrates \[reviewed in ([@R357]; [@R537])\]. Gene transcription is in turn tightly controlled by epigenetic mechanisms ([@R59]). Epigenetic mechanisms regulate the accessibility of deoxyribonucleic acid (DNA) to transcription-initiating machinery via certain molecular events including histone tail post-translational modifications and DNA methylation. In this section we will focus on histone acetylation and DNA methylation, with emphasis on their dynamic interactions within the chromatin environment that orchestrate the regulation of genes at the molecular level, and review accumulating evidence that modulation of extinction-relevant receptors at the synapse can initiate epigenetic programs within the nucleus and modulate extinction in a persistent and context-independent manner. We will also review data showing that drugs targeting epigenetic mechanisms may serve to strengthen extinction.

### 4.10.1. Histone modifications {#S25}

To date, a main focus of research is on understanding the interaction between histone modifications and the strengthening of fear extinction memories. In eukaryotic cells, DNA is organized in a highly conserved structural polymer, termed chromatin. The basic building block of chromatin is the nucleosome, which consists of 146 base pairs (bp) of DNA wrapped around an octamer consisting of (dimers of) core histone proteins (H2A, H2B, H3, and H4) held together by a H1 linker protein ([@R259]). Histones contain a globular domain with a covalently modifiable N-terminal tail consisting of lysine and/or arginine residues. Histone modifications constitute a signal that is read alone or, in combination with other modifications and interactions with neighboring histones -- a 'histone code' ([@R261]). At least 9 different posttranslational modifications, including acetylation, phosphorylation, methylation, biotinylation, SUMOylation, ADP ribosylation, and ubiquitination, influence chromatin condensation, resulting in gene transcription by coordinating protein and enzyme complex accessibility to DNA ([@R446]). Here, we focus primarily on the most well-studied histone modification in extinction -- acetylation of histone proteins.

Histone acetylation on lysine (K) residues leads to transcriptional activation by neutralizing the positive charge of the K ε-amino group of histone tails, which in-turn relaxes chromatin by reducing the electrostatic bonding of histone with negatively charged DNA ([@R169]). The enzymes involved in regulating this process are 1) histone acetyltransferases (HATs), also known as lysine acetyltransferases (KATs) ([@R9]) or 'writers' ([@R357]) and 2) histone deacetylases (HDACs), also known as lysine deacetylases (KDACs) ([@R78]) or 'erasers' ([@R357]). HATs acetylate K residues to promote gene transcription, whereas HDACs, which are present in co-repressor complexes, remove K residues to impair gene transcription (see [Fig. 9](#F9){ref-type="fig"}.) \[for greater detail, see ([@R140])\].

There is some evidence that extinction is associated with alterations in HAT activity and that drugs increasing HAT activity could constitute a novel approach to augmenting extinction ([Fig. 9](#F9){ref-type="fig"}.). Following extinction, there is increased expression of the HAT p300/CBP-associated factor (PCAF) in the rodent IL, and intra-IL infusion of the PCAF activator, SPV106, facilitates extinction and protects against fear renewal ([@R530]). However, inhibiting, rather than activating, the activity of another HAT, p300, in the IL also strengthens extinction ([@R318]). One possible explanation of this finding is that rather than strengthening extinction, p300 may bolster fear memory reconsolidation via transcription of genes including nuclear factor κB (NF-κB) ([@R147]; [@R409]) and yin-yang 1 (YY1) ([@R555]), known to be involved in reconsolidation ([@R152]; [@R306]). These two studies that demonstrate how targeting HATs affects fear in different ways indicate the need for additional work to determine the optimal approach to facilitate extinction with HAT modulators.

There is an increasing amount of evidence to suggest that histone acetylation is an important mechanism promoting successful fear extinction (reviewed in ([@R537])\] ([Fig. 9](#F9){ref-type="fig"}.). An important early study found that histone extinction is associated with increased acetylation of histone H4 in the promoter region of bdnf exon IV ([@R45]). Subsequent work showed that administration of various HDAC inhibitors including TSA (trichostatin A), sodium butyrate, entinostat (MS-275), vorinostat (SAHA, suberoylanilide hydroxamic acid), VPA (valproic acid) and Cl-944 can augment fear extinction ([Table 10](#T16){ref-type="table"}). The potential clinical utility of using HDAC inhibitors has been further strengthened by showing that Cl-944, MS-275 and SAHA rescue extinction deficits in various rodent models ([@R163]; [@R187]; [@R326]; [@R536]) (see [Table 10](#T16){ref-type="table"}).

An additional attribute of HDAC inhibitors is their ability to extinguish remote (aged) fear memories that are normally resistant to extinction. Extinction of recent fear memories (1 day after conditioning), using a memory update-consolidation paradigm, increases HDAC2 nitrosylation ([@R163]), which facilitates the dissociation of HDAC2 from chromatin ([@R379]), leading to histone hyper-acetylation and HPC expression of extinction-relevant genes including c-Fos. By contrast, nitrosylation of HDAC2 and c-Fos expression do not increase after extinction training of remote (1 month post conditioning) fear memories ([@R163]) ([Fig. 9](#F9){ref-type="fig"}.). Systemic administration of the HDAC inhibitor Cl-994 was able to rescue remote extinction and the associated gene expression deficits. Rescue of impaired remote extinction has been observed with dietary zinc restriction, which inhibits HDAC in addition to affecting other systems ([@R223]; [@R535]). Collectively, these two studies support the potential clinical utility of HDAC inhibitors as adjuncts to CBT treatment of fearful memories that started long after the exposure to trauma.

Further supporting a role of HDAC activity in the modulation of fear extinction mechanisms is the observation that reduced HDAC activity is associated with improvements in fear extinction ([@R187]). At present 18 different mammalian HDAC isoforms have been identified, and they are divided into four classes (Classes I--IV). Targeting individual HDAC isoforms is an important aim of drug development ([@R169]). The majority of currently available HDAC inhibitors target multiple isoforms of the HDAC family (e.g. classes I, II, and IV), while some of the HDAC inhibitors that have proved to be successful in augmenting fear extinction ([Table 10](#T16){ref-type="table"}) exhibit preferential selectivity towards class-I HDACs (encompassing HDAC1, HDAC2, HDAC3 and HDAC8) ([@R186]).

Studies using gene knockdown or over-expression suggest that targeting specific HDAC isoforms could indeed be a promising approach to modulating extinction \[reviewed in ([@R537])\]. This is exemplified by the recent finding that gene silencing of HDAC2, but not HDAC1, in forebrain neurons promotes extinction ([@R360]). However, the effect of specifically inhibiting other HDAC isoforms, including HDAC3 \[recently shown to facilitate the extinction of drug-seeking memories ([@R314])\], remains to be tested.

It is likely that the extinction-facilitating effects of HDAC inhibitors are due to activation of extinction-related gene transcription programs. The HDAC inhibitors SAHA and VPA increase, respectively histone acetylation in the promoter region of *grin2b* (NMDA receptor subunit 2B) ([@R146]), and histone H4 acetylation in promoter IV of bdnf, leading to increased BDNF exon IV mRNA expression ([@R45]). In addition, the HDAC inhibitor Cl-994 increases histone H3 acetylation in the promoter region of plasticity associated genes including *igf2, adcy6, c-Fos, npas4*, and *arc* ([@R163]). Indeed, a range of neurotransmitter/neuromodulator systems that are known to mediate extinction, induce transcription of relevant genes via enhancement of histone acetylation, including histone H3 acetylation in the promoter region of *bdnf, camk2a, creb* and the NMDA receptor subunit genes *grin2a* and *grin2b* ([@R462]; [@R511], [@R512]; [@R520]). Concerning a possible convergent downstream mechanism for these effects, serotonin via activation of PKA signaling pathways ([@R172]), L-type calcium channel activation ([@R115]) and BDNF/TrkB activation ([@R88]) all activate the MAPK/ERK signaling pathway, which is crucial for fear extinction ([@R399]) (see also [Fig. 3](#F3){ref-type="fig"}). MAPK/ERK signaling to the nucleus could increase histone acetylation by enhancing activity of the HAT CREB-binding protein (CBP) ([@R80]).

### 4.10.2. DNA methylation {#S26}

DNA methylation is a crucial mechanism for controlling chromatin remodeling in the adult mammalian nervous system ([@R291]; [@R372]) and can occur at multiple sites within a gene. DNA methylation is a direct chemical modification of a cytosine side-chain that adds a methyl (--CH3) group through a covalent bond, catalyzed by a class of enzymes known as DNA methyltransferases (DNMTs)([@R385]). The DNMTs transfer methyl groups to cytosine residues within a continuous stretch of DNA, specifically at the 5′-position of the pyrimidine ring (5-methylcytosine) ([@R72]). Not all cytosines can be methylated; typically, cytosines are followed by a guanine in order to be methylated ([@R96]) ([Fig. 9](#F9){ref-type="fig"}.). However, given the recent finding that methylation can occur outside CpG islands and in CpH (where H = adenine/cytosine/thymine) islands and that these CpH islands can repress ([@R180]) substantially expands and adds further complexity to how methylation can regulate gene transcription in the central nervous system. Furthermore, this finding raises the open question of whether CpH methylation is a molecular mechanism regulating fear extinction.

In a pioneering study, linking DNA methylation and extinction, extinction-resistant female mice were found to exhibit increased DNA methylation of Bdnf exon IV and a concomitant decrease in BDNF mRNA expression in the PFC ([@R22]). The fact that DNA methylation is reversible suggests that enhancement of gene transcription by DNA demethylation could represent a novel mechanism for strengthening extinction that has the potential to be pharmaceutically exploited. Along these lines, the ten-eleven translocation (Tet) family of methylcytosine dioxygenases, which includes Tet1, Tet2, and Tet3 enzymes, catalyze oxidation of 5-methylcytosine to 5-hydroxymethylcytosine and thereby promotes DNA demethylation ([@R232]; [@R502]).

Two recent studies demonstrate the importance of these Tet enzymes in extinction. Extinction leads to a genome-wide redistribution of 5-hydroxymethylcytosine and Tet3 occupancy to extinction-relevant genes including the GABA~A~ clustering protein, gephyrin (see Section 4.5: γ-*aminobutyric acid* (*GABA*)), and to enhanced gephyrin mRNA expression in the IL ([@R293]). Furthermore, gene knockdown of Tet1 impairs extinction ([@R445]). While agents targeting Tet enzymes are not currently available, these emerging pre-clinical findings may provide the impetus to develop such compounds.

### 4.10.3. Non-coding RNA {#S27}

In addition to histone modifications and DNA methylation, gene expression is also regulated by non-coding RNAs including micro-RNAs (miRNAs) ([@R485]). miRNAs represent classes of non-coding RNAs that mediate post-transcriptional regulation of gene expression, including genes associated with synaptic plasticity, learning and memory ([@R28]). Although miRNAs are usually associated with preventing mRNA translation and thereby with suppressing new protein synthesis, a specific miRNA was recently shown to augment fear extinction. Fear extinction enhanced the expression of miR-128b in the IL associated with down-regulation of plasticity-related genes including creb1 and sp1 in tandem with inhibition of the original fear memory ([@R299]). Clearly, further clarification of the role of non-coding RNAs during fear extinction is warranted, including through the development of tools by which specific non-coding RNAs can be modulated.

5. Discussion and final conclusions {#S28}
===================================

In this review we aimed to summarize (druggable) systems involved in fear extinction and how pharmacological compounds have been utilized to augment fear extinction in preclinical and small-scale clinical studies. It is anticipated that these findings are paving the way for clinical use of such approaches given that extinction training is procedurally similar to exposure-based psychotherapy and the underlying fear/extinction circuitries and molecular mechanisms are well conserved across species ([@R351]). As mentioned in the introduction, the main problems with current exposure-based CBT treatment of fear, anxiety and trauma-related disorders are that a significant proportion of patients either: 1) have difficulties bearing the demanding and exhausting process of this therapy, 2) do not, or not sufficiently, respond to the therapy -- failing to substantially reduce their fear response, or 3) responds initially, but suffer from return of fear phenomena hampering remission and full recovery. In this review we summarize the pharmacological approaches that have been investigated and utilized to improve these shortcomings. Initial attempts to combine exposure-based CBT with pharmacotherapy included benzodiazepines that dampened anxiety but also reduced the learning effects of this procedure hence provoking return of fear symptoms upon discontinuation ([@R214]; [@R387], [@R388]). A complicating issue is the observation that the interoceptive state induced by such anxiolytics can form part of a "context", and consequently may promote fear in subsequent testing in an "off drug state", leading to state-dependent learning due to a change in interoceptive context ([@R320]). However, there is evidence that targeting novel anxiolytic systems such as the NPS system or fibroblast growth factor-2 may elicit acute anxiolytic effects without producing sedation, state-dependency and/or interference with the formation of extinction memories. These findings are particularly exciting as they are beginning to address one of the important problems associated with CBT (i.e. intolerability to CBT exposure). However, more research is necessary to prove the utility of such approaches. As well as improving tolerability to exposure, improvements concerning onset, magnitude and duration of the therapeutic effect of exposure-based CBT are also in the main focus of drug development in this field. As outlined in this review, the augmentation of fear extinction/exposure therapy with a range of different drugs acting as cognitive enhancers to strengthen extinction memories represents an important approach to enhancing therapy efficacy. This has been made possible by revealing the neurochemical/neurobiological responses within the neural circuitry whose activity is required for fear extinction and, by extension, to rescue fear extinction deficits.

Considerable progress has been made in defining the neural basis of fear extinction and fear extinction deficits (for recent reviews see ([@R351]; [@R223]; [@R404]). The steadily growing knowledge concerning where and how fear extinction is processed and how it can be pharmacologically augmented is an essential platform from which to identify promising candidates for extinction-promoting therapeutics. Indeed, by successfully translating findings from animal models, progress has been made in enhancing the outcomes of exposure-based CBT using compounds such as DCS, yohimbine and glucocorticoids as cognitive enhancers in the treatment of patients with anxiety disorders, PTSD and OCD ([@R217]; [@R331]; [@R378]).

As outlined in this review, an impressive number of additional extinction augmenting drugs, acting on a wide variety of pharmacological targets, have indeed been identified. Data arising from the use of animal models displaying deficient fear extinction, reflecting patients resistant to exposure therapy, indicate that different neurotransmitter/neurobiological signaling pathways are involved in different temporal phases of extinction. Hence, it is likely that different pharmacological approaches will be required to either induce fear reductions during extinction training or rescue/boost the consolidation of fear extinction (reviewed in ([@R223]). The important finding that within-session fear reduction/habituation favors drug-augmented extinction rather than facilitating reconsolidation of existing fear memories ([@R164]; [@R344]) has also been demonstrated in clinical trials using DCS (([@R215]) and yohimbine ([@R476]). Moreover, multi-target approaches that simultaneously modulate the activity of diverse neurotransmitter/neurobiological systems seem to be an important option to pursue, in particular for individuals with severe extinction deficit/resistance to exposure therapy. Interestingly, in the much more well established medical fields of infectious disease, hypertension, oncology, and similar areas, targeting multiple different mechanisms of action is also the norm, not the exception and it is also considered promising in other fields of psychiatry ([@R352]).

One of the most important aspects of extinction-promoting drugs is their ability to bolster extinction by enhancing memory consolidation. It is likely that this extinction enhancement occurs via the enhancement of cortico-AMY synaptic plasticity through multiple mechanisms (reviewed in ([@R368]; [@R468]; [@R386]; [@R122]), ultimately providing lasting effects and better protection from return of fear phenomena. If translated into clinical use, these effects would support sustained symptom remission and recovery. Some of the drug targets outlined in this review \[e.g. epigenetic targets including histone modification, BDNF and facilitated dopaminergic and fibroblast-growth-factor-2 signaling) and also cholinergic targets -- see ([@R563])\] seem to be promising in this respect, as they promote long-term and context-independent fear inhibition when combined with fear extinction. Context-independent extinction learning (extinction generalization) offering enhanced protection against fear return phenomena such as renewal, may be supported not only by targeting specific pharmacological mechanisms, but also by behavioral approaches (see below). Fortunately, some of the promising substances in that respect are approved for human use (e.g. Valproate, L-DOPA, FGF2) and thus, their extinction-augmenting capacity could be immediately examined in anxiety and trauma-focused clinical trials. Although some of the discussed agents may share important common downstream signaling pathways, it seems clear that there are a number of different pharmacological pathways to access the circuits that underlie fear extinction learning and memory (see [Fig. 3](#F3){ref-type="fig"}), which will enable even more specific targeting of the essential extinction-promoting mechanisms in the future.

Despite this clear progress there remain major challenges for the development of medications to improve the effectiveness of exposure-based therapies, including challenges related to the design of safe, brain-penetrant molecules with limited adverse side-effects. Individual differences in treatment tolerability and efficacy, caused by genetic variation, and prior medication history are further complicating concerns. For example, the careful dissection of the brain regions mediating fear extinction including the AMY, PFC, HPC and other regions has also shown that some systems can promote both extinction-facilitating and extinction-impairing effects depending on the brain area/cellular substrate they are acting on. An example is the β-adrenoceptor, blockade of which interferes with extinction when restricted to the IL, but promotes extinction when the BLA is targeted -- hence it is difficult to predict the net effect of medicating a patient with a β-adrenoceptor blocker or agonist during exposure therapy. The targeting of specific intracellular signaling cascades might be a solution for future, more selective approaches in this direction. Research in the last few years has revealed that the specific ligands can bias the signal output of G-protein coupled receptors by stabilizing the receptor structure in a distinct way to the natural ligand. By providing a means to produce functional selectivity, biased agonists and antagonists may be utilized to activate preferential, even unnatural, signaling cascades mediating the therapeutically favored downstream biological consequences \[for a recent review see ([@R309])\].

Another important aspect for future clinical implementation of drug-induced facilitation of exposure therapy outcome concerns the time course of drug administration. While current drug treatment for anxiety and trauma-related disorders involves mainly chronic treatment (e.g. with SSRIs, SNRIs, TCA, MAOI) the compounds discussed in this review are (with the exception of antidepressants) recommended to be applied acutely in combination with psychotherapeutic interventions for a limited number of exposure trials. This strategy includes several advantages: First, chronic application of drugs can induce very different biological effects from those observed with acute administration. It is extremely challenging to predict how and at which stage (recall of fear memory, learning, reconsolidation, consolidation, retrieval of extinction memory) chronically applied drugs will enhance/interfere with fear extinction. For example, it is likely that facilitation of extinction and disruption of fear reconsolidation, both leading to fear reduction, depend on opposing molecular processes, such that chronic administration of the same drug may lead to very different therapeutic outcomes depending on which process (i.e. extinction or reconsolidation) it enhances ([@R164]). Second, acute administration implies a reduced side effect potential. One example is the addiction potential of some of the compounds currently examined for extinction augmentation (e.g. MDMA). Indeed, first clinical trials reported that none of the involved patients developed a substance abuse problem when MDMA was administered acutely to assist psychotherapy ([@R355]).

In addition to pharmacological parameters, the efficacy and duration of exposure therapy in humans may also depend (as shown in animal studies) on manipulation of specific behavioral extinction training parameters \[see also e.g. ([@R100]; [@R454])\] such as providing sufficient extinction training, enhancing the number of contexts for such training, trial spacing, and other approaches (reviewed in [@R207]; [@R141]). It will be an important future line of research to test the optimal combinations between such behavioral interventions and the outlined pharmacological approaches in order to maximize treatment outcome. It is also important to note that thought needs to be given to a variety of factors concerning how to optimally utilize adjunctive and novel treatments. Such factors include consideration of monotherapy vs. add-on adjunctive treatment; use of medications in drug naïve vs. already medicated subjects; combined use of medication explicitly with exposure/extinction psychotherapy vs. medication taken without explicit psychotherapy; timing of medication -- e.g. at night to aid memory consolidation during sleep vs. immediately before or after exposure; and use of medications in countries with well-developed vs. poorly developed health systems. As the field of psychopharmacotherapy matures beyond the models that it has followed for decades, all of these considerations are important for new drug development. For example some medications may not be as efficacious in subjects with a history of antidepressant use, as has been suggested for D-cycloserine ([@R533]). Furthermore, as sleep is increasingly thought to be associated with extinction learning, targeting medication to enhance the memory consolidation process during sleep may be important ([@R392]). Finally, medications which are available readily in generic form and that do not require specialized adjunctive psychotherapy may be more readily disseminated to locations with less well-developed mental health care systems than those that are novel, or more expensive, or that may require specialized combined therapy. Taken together, these considerations remind us that identifying molecular mechanisms and novel drug approaches to fear regulation is only part of the challenge, and that the context of the dissemination of such new therapeutics is also of critical concern.

In summary, based on the evidence outlined in this review, the next few years promise to produce several novel clinical approaches to treating trauma- and anxiety-related disorders in a more efficient and persistent way that will most likely lead to enhanced symptom remission. Progress will depend on translational research approaches and a close interaction between preclinical and clinical researchers. [Fig. 10](#F10){ref-type="fig"} outlines how the different levels of understanding, from genetics to epigenetics to neural circuits, can inform each other as well as how they can be informed across species due to the high level of convergence of shared fear-related processing across mammals. This research and the considerable number of compounds to choose from in the growing pharmacological tool box in this field, many of which display minimal side effects, may enable psychiatrists/psychologists to individualize drug treatment according to specific symptoms of anxiety disorders, PTSD and OCD. Such options are expected to further improve treatment outcome and to reduce the amount of psychotherapy sessions needed, or the duration or intensity that is required for long-lasting treatment success. As outlined above, evidence is beginning to shape the hypothesis that specific classes of compounds and cognitive enhancers may be superior to others in their ability to support long-term fear-inhibiting effects. There is evidence that the efficacy of different classes of drugs may be distinctly influenced by a number of factors including age, gender and other examples of individual differences. Hence, future research is warranted in order to investigate whether specific drugs used as cognitive enhancers in this field are more or less appropriate for specific individuals, conditions and treatment durations. In conclusion, cognitive enhancers present a promising option to safely augment extinction-based anxiety- and trauma therapy and to reduce treatment duration, thereby facilitating treatment coherence and outcomes.
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5-HT

:   5-hydroxytryptamine = serotonin

AC

:   adenylate cyclase

AMPA

:   α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid

AMY

:   amygdala

BA

:   basal amygdala

BDNF

:   brain-derived neurotrophic factor

BLA

:   basolateral amygdaloid complex

BZD

:   benzodiazepine

CaMKII

:   Ca2+/calmodulin-dependent protein kinase II

cAMP

:   3′-5′-cyclicadenosine monophosphate

Cav 1.2

:   L-type calcium channel alpha 1C isoform

Cav 1.3

:   L-type calcium channel alpha 1D isoform

CBT

:   cognitive behavioral therapy

CCK

:   cholecystokinin

CeA

:   central amygdala

CeM

:   centromedial amygdala

CeL

:   centrolateral amygdala

CNS

:   central nervous system

CREB

:   cAMP response element binding

CS

:   conditioned stimulus

DA

:   dopamine

DCS

:   [d]{.smallcaps}-cycloserine

DNA

:   deoxyribonucleic acid

eCB

:   endogenous cannabinoiod

ERK

:   extracellular regulated kinase

ERP

:   exposure and prevention CBT

FGF2

:   fibroblast growth factor-2

GABA

:   γ-aminobutyric acid

GABA~A~

:   GABA~A~ receptor

GAD

:   generalized anxiety disorder

GAD (65/67)

:   glutamate decarboxylase 65/67

GluN

:   NMDA receptor subtype

GR

:   glucocorticoid receptor

H3

:   histone H3 protein

H4

:   histone H4 protein

HAT

:   histone acetyltransferase

HDAC

:   histone deacetylase

HDAC2

:   histone deacetylase 2

HPA

:   hypothalamic-pituitary-adrenal axis

HPC

:   hippocampus

icv

:   intracerebroventricular

IL

:   infralimbic cortex

ITC

:   intercalated cell masses

K

:   lysine

KOR

:   kappa opioid receptor

LA

:   lateral amygdala

L-DOPA

:   levodopa

MAPK

:   mitogen-activated protein kinase

MDMA

:   3,4-methylenedioxy-N-methylamphetamine

Mg2+

:   magnesium ion

mGluR

:   metabotropic glutamate receptor

miRNA

:   micro-RNA

mPFC

:   medial prefrontal cortex

mRNA

:   messenger ribonucleic acid

MS-275

:   entinostat (Pyridin-3-ylmethyl N-\[\[4-\[(2-aminophenyl)carbamoyl\] phenyl\]methyl\]carbamate)

NMDA

:   N-methyl-[d]{.smallcaps}-aspartate

NMDAR

:   NMDA receptor

ns

:   not studied

NO

:   nitric oxide

NPS

:   neuropeptide S

NPY

:   neuropeptide Y

OCD

:   obsessive-compulsive disorder

OXT

:   oxytocin

PAG

:   periaqueductal gray

PEPA

:   4-\[2-(Phenylsulphonylamino)ethylthio\]-2,6-difluorophenoxyacetamide

PKC

:   as Ca2+ /phospholipid-dependent protein kinase C

PTSD

:   post-traumatic stress disorder

PL

:   prelimbic cortex

SAD

:   social anxiety disorder

SAHA

:   vorinostat(N-hydroxy-N'-phenyl-octanediamide)

SNP

:   single nucleotide polymorphism

SNRI

:   selective noradrenaline reuptake inhibitor

SSRI

:   selective serotonin reuptake inhibitor

TrkB

:   tropomyosin-related kinase B

US

:   unconditioned stimulus

VGCC

:   voltage-gated calcium channel

VRET

:   virtual reality exposure

Zn2+

:   zinc ion

![Different modes of fear alleviation and sites of possible pharmacological intervention. A, Fear alleviation is mediated via different mechanisms leading to acute or sustained fear relief. Sustained fear relief can be obtained either with exposures to the feared cues/situations or, in some instances, also without them For a detailed description of the involved mechanisms, see [@R434]. Pharmacological interventions to boost fear relief can target different mechanisms at various levels. Examples are given with numbers 1--4, for detail see text B, Fear conditioning represents a training phase in which a novel conditioned stimulus (CS) is paired with an unconditioned stimulus (US) (redline). Throughout fear training and testing, fear is measured as a conditioned response (y-axis), typically freezing, fear-potentiated startle, increased heart rate, and other quantifiable behavioral measures of fear. Following this training period, mice undergo a consolidation phase which transfers the labile newly formed fear memory into a stable long-term memory. Fear can be extinguished by repeated presentations of the CS (without the US; red line) resulting in fear extinction. Following the extinction training session, and akin to fear learning, consolidation processes are initiated to stabilize this labile fear extinction memory into a long-term memory. Poor extinction is evidenced by high fear responding (red bar), and successful extinction retrieval is shown by reduced fear (green) during a retrieval test. Extinguished fear can recover via three main mechanisms: spontaneous recovery (recovery of extinguished fear responses occurs with the passage of time in the absence of any further training), fear renewal (when the conditioned CS is presented outside the extinction context, for example the conditioning or novel contexts), and fear reinstatement (when un-signaled presentations of the US are interposed between the completion of extinction training and a subsequent retention test). Drugs (green arrows) can be administered either immediately prior to (to induce extinction acquisition also called 'within-session extinction' and/or extinction consolidation) or immediately following (to rescue/ boost extinction consolidation processes) the training session to modulate extinction mechanisms. A clinical aim of drug augmentation strategies is to promote good extinction retrieval and to protect against return-of-fear phenomena to provide good 'longterm extinction'. C, Fear memory can be reactivated (red bar) by presentation of the CS, which transfers the stabilized memory into a labile phase which requires reconsolidation (a process by which previously consolidated memories are stabilized after fear retrieval). The fear memory can then be tested during another retrieval test (red bar) to assess reconsolidation. Drugs (green arrow) can be administered either immediately prior to or after the retrieval session to modulate reconsolidation mechanisms. This effect can then be tested during subsequent retrieval tests. Evidence for successful interference with reconsolidation of the original fear memory is revealed in reduced freezing during the test session. (For interpretation of the references to color in this figure legend, the reader is referred to the web version of this article.)](nihms670509f1){#F1}

![Anatomy of fear extinction and expression. Fear extinction and expression rely on neuronal processing in an anatomical circuitry centering on the AMY, mPFC, and HPC Glutamatergic and GABAergic neurons, among others, are important components of connectivity and regulation of fear. The AMY is critically involved in the expression of aversive (fear) memories. While fear neurons in the BA send excitatory projections directly to the centromedial AMY (CeM) driving expression of fear (right panel), during extinction (left panel), the infralimbic cortex (IL) inhibits CeM output by driving inhibitory ITC neurons. IL inputs might also synapse directly on "extinction" neurons within the BA. "Extinction" neurons can influence activity within the central AMY (CeA) through several routes, possibly by driving inhibitory ITC or CeL (off, PKC+) neurons that limit CeM activity. There is also a BA-CeL pathway contributing to ultimate inhibition of the CeM. The hippocampus is involved in contextual aspects of extinction via its projections to both the IL and the BA, among other brain regions. Hence, inhibitory memories built following extinction are encoded by the AMY and the mPFC and are modulated by the HPC. It is thought that extinction training and exposure therapy produce long-lasting changes in synaptic plasticity and interneuronal communication in this circuitry ultimately reducing fear responses via output stations including the CeM. For further details, the reader is refered to recent reviews of ([@R122]; [@R386]).](nihms670509f2){#F2}

![Overview of pharmacological targets and signaling cascades proposed to be important in mediating synaptic plasticity underlying extinction. The formation of extinction memories requires an intricate regulatory network of signal transduction and gene transcription and translation, leading to a complex pattern of intracellular changes and long-term structural changes. Various pre- and postsynaptic membrane receptors including ionotropic and metabotropic glutamate receptors, cannabinoid receptors, 5-HT, and dopamine receptors have been shown to be important targets. Main downstream mechanisms include calcium entry through NMDAR and VGCC in concert with AMPA receptors initiating synaptic plasticity via calcium-dependent protein kinases (e.g. PKA, PKC, PKM and CamKII, phosphatases (e.g. calcineurin) and activation of the ERK/MAPK pathway. Subsequent interaction with transcription factors, such as CREB and Zif268 within the nucleus results in a wide range of newly synthesized proteins, such as BDNF important for synaptic plasticity including LTP formation. BDNF activated TrkB receptors further regulate the ERK/MAPK pathway. Finally, epigenetic modifications are important in translating neurotransmitter/neuromodulator signaling activity generated at the synapse into activation/repression of the desired genomic response in the cell nucleus. As outlined in the text, boosting these synaptic plasticity mechanisms by pharmacological means may constitute the establishment of novel drug targets to promote fear extinction.](nihms670509f3){#F3}

![Overview of research on the role of the serotonergic system in extinction.](nihms670509f4){#F4}

![Overview of research on the role of the dopaminergic system in extinction.](nihms670509f5){#F5}

![Overview of research on the role of the glutamatergic system in extinction](nihms670509f6){#F6}

![Overview of research on the role of the GABAergic system in extinction.](nihms670509f7){#F7}

![Overview of research on the role of the cannabinoid system in extinction.](nihms670509f8){#F8}

![Schematic representation depicting the epigenetic regulation of fear extinction. DNA methylation is associated with suppression of gene transcription. The precise molecular processes through which this occurs are complex. In brief, methylation of cytosines at CpG dinucleotides recruits methyl-DNA binding proteins, at specific sites in the genome. Proteins that bind to methylated DNA, including methyl CpG-binding protein 2(MeCP2) and methyl CpG-binding domain protein1 (MBD1), have both a methyl-DNA binding domain and a transcription-regulatory domain. The transcription-regulatory domain recruits adapter/scaffolding proteins, which in turn recruit HDACs, including HDAC2, to repress gene transcription \[reviewed in ([@R498]). Following extinction related neuronal activity a number of molecular mechanisms are invoked, ultimately leading to facilitated histone acetylation and subsequent enhancement of gene transcription. These mechanisms include enhancement of HAT activity, such as PCAF (see text) and a reduction in HDAC activity by mechanisms which include nitrosylation (NO) of HDACs, including HDAC2, which facilitates dissociation of HDAC from the chromatin. Moreover, enhanced histone acetylation may also be mediated by the conversion of DNA demethylation which is mediated by the Tet family of methylsytosine dioxygenases. Emerging pharmaceutical evidence is showing that HDAC inhibitors can facilitate gene transcription by enhancing histone acetylation in the promoter region of extinction-relevant genes (see text).](nihms670509f9){#F9}

![Strategy for translating research from humans to mice and back, focusing on human disorders of fear dysregulation. Rodent models of enhanced fear and impaired extinction (induced by genetic or environmental manipulations) closely resemble human symptomatology, particularly the fear dysregulation that occurs in PTSD, panic, and phobic disorders. Using these models increases the chances of identifying candidate genes for human anxiety disorders by reducing the problems of genetic heterogeneity and a variable environment. It is also important to study the involvement of these candidate genes in patients, as well as using unbiased genome-wide association studies and genome-wide epigenetic approaches to identify previously unknown genetic pathways contributing to risk in humans. Subsequently, elucidating the function of the identified gene and its epigenetic regulation using rodent models as well as the human population increases our knowledge of the neurobiology of fear disorders, which, at the same time, is necessary to improve the models. It is also necessary to use rodent models to test the ability to pharmacologically enhance extinction of fear and diminish fear expression prior to clinical test phases. Arrows demonstrate how the different levels of understanding, from genetics to epigenetics to neural circuits, can inform each other, as well as how they can be informed across species due to the high level of convergence of shared fear-related processing across mammals.](nihms670509f10){#F10}

###### 

Serotonergic signaling in fear extinction (preclinical studies).

  Drug/manipulation                        Extinction training                                                 Extinction retrieval                                                 Longterm extinction     Route     Reference
  ---------------------------------------- ------------------------------------------------------------------- -------------------------------------------------------------------- ----------------------- --------- --------------------
  *Facilitating 5-HT signaling*                                                                                                                                                                                       
  SERT KO[6](#TFN6){ref-type="table-fn"}   ns                                                                  --                                                                   ns                      No drug   ([@R194])
                                           No effect                                                           --                                                                   ns                      No drug   ([@R532])
  Acute fluoxetine (SSRI)                  (−)[\#\#](#TFN9){ref-type="table-fn"}                               No effect                                                            ns                      ip        ([@R280])
  Subchronic citalopram (SSRI, 9d)         No effect                                                           ns                                                                   ns                      ip        ([@R50])
  Chronic citalopram (SSRI, 22d)           --                                                                  (−)                                                                  ns                      ip        ([@R50])
  Chronic (14d) fluoxetine (SSRI)          (+)[\#](#TFN8){ref-type="table-fn"}                                 (+)                                                                  ns                      po        ([@R280])
  Chronic fluoxetine (SSRI)                No effect                                                           \+                                                                   \+ (Ren-A, SR, Re-in)   ip        ([@R243])
                                           No effect                                                           ns                                                                   \+ (Re-in)              ip,po     ([@R108], [@R109])
                                           No effect[\*](#TFN7){ref-type="table-fn"}                           \+[\*](#TFN7){ref-type="table-fn"}[4](#TFN4){ref-type="table-fn"}    ns                      po        ([@R60])
                                           No effect                                                           \+                                                                   ns                      po        ([@R418])
  Acute venlafaxine (SSRI)                 No effect                                                           \+                                                                   ns                      ip        ([@R554])
  Chronic venlafaxine (SSRI)               ns                                                                  ns                                                                   \+ (Re-in)              ip        ([@R554])
  8-OH-DPAT (5HT1 ag)                      \+[\*](#TFN7){ref-type="table-fn"}[5](#TFN5){ref-type="table-fn"}   (−)[\*](#TFN7){ref-type="table-fn"}[5](#TFN5){ref-type="table-fn"}   ns                      ip        ([@R528])
  Tandospirone (5HT1 ag)                   ns                                                                  \+[\*](#TFN7){ref-type="table-fn"}                                   ns                      ip        ([@R447])
  tcb2 (5HT2A ag)                          \+                                                                  ns                                                                   ns                      ip        ([@R564])
  Psilocybin (5HT2A ag)                    (+)                                                                 ns                                                                   ns                      ip        ([@R65])
  5-HT3 OE                                 No effect                                                           ns                                                                   ns                      No drug   [@R188]
  *Inhibiting 5-HT signaling*                                                                                                                                                                                         
  5,7-Dihydroxytryptamine                  (+)[\#](#TFN8){ref-type="table-fn"}                                 \+                                                                   ns                      BLA       ([@R234])
  5,7-Dihydroxytryptamine                  No effect                                                           No effect                                                            ns                      IL        ([@R234])
  5HT3 KO                                  ns                                                                  --                                                                   ns                      No drug   ([@R257])
  MDL11,939 (5HT2A ant)                    --                                                                  ns                                                                   ns                      ip        ([@R564])
  Ketanserin (5HT2A/C ant)                 (+)                                                                 ns                                                                   ns                      ip        ([@R65])
  Granisetron (5HT3 ant)                   No effect                                                           (+)                                                                  ns                      ip        [@R400]

drug administration following extinction training;

SERT-KO results in increased synaptic 5-HT levels;

7 days;

protection from context over-generalization;

valproate-induced model of autism,

SERT-KO results in increased synaptic 5-HT levels.

facilitates rescue of impaired fear extinction;

reduced fear expression at the beginning of extinction training;

enhanced fear expression at the beginning of extinction training.

+, improved; -, impaired; (+) or (−), only minor effects; po, peroral administration; ip, intraperitoneal injection; ns, not studied; BLA, intra-basolateral amygdala administration; IL, infralimbic cortex; Ren-A, Fear renewal in conditioning context; SR spontaneous recovery; Re-in, reinstatement; ag, agonist; ant, antagonist, KO, knock-out; OE, over-expression.

[In "Extinction training" (or]{.ul} 'within-session extinction'), an effect on the reduction of the behavioral response (e.g. freezing) in response to repeated CS presentations is described.

[In "Extinction retrieval",]{.ul} an effect on the recall of the extinction memory 24h following extinction training is described.

[In "Long-term extinction"]{.ul} an effect on the robustness of the extinction memory in terms of protection against spontaneous recovery of fear (passage of time), fear renewal (re-exposure to conditioning context or a novel context which is distinct to the conditioning and extinction context) and fear reinstatement (US re-exposure) is described.

In this review we aimed to summarize (druggable) systems involved in fear extinction and how pharmacological compounds have been utilized to augment fear extinction in preclinical (rodent) and small-scale clinical studies. We did not differentiate between data gained from either mice or rats as this would have gone beyond the scope of this review. However, excellent species differentiation has been provided by others (e.g. ([@R313], [@R367], [@R42], [@R433], [@R49], [@R141]).

###### 

Human trials: serotonergic drugs combined with CBT.

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Disorder                       Study design                                             Outcome (compared to placebo control group)                    Reference
  ------------------------------ -------------------------------------------------------- -------------------------------------------------------------- -----------
  Healthy volunteers             14 days po escitalopram pretreatment; fear\              Accelerated extinction learning (skin conductance responses)   ([@R47])
                                 conditioning paradigm                                                                                                   

  Panic disorder with/without\   Fluvoxamine or placebo followed by exposure\             Self-reported measures\                                        ([@R98])
  agoraphobia                    therapy; psychological panic management followed\        All treatments effective, however fluvoxamine plus CBT\        
                                 by exposure therapy or exposure therapy alone            superior to all other treatments                               

  Panic disorder with/without\   12 weeks paroxetine or placebo plus CBT                  Reduced number of panic attacks in paroxetine/CBT group        ([@R382])
  agoraphobia                                                                                                                                            

  Panic disorder with/without\   10 weeks of paroxetine or placebo plus CBT in week 5\    No significant difference in primary CGI outcome.\             ([@R488])
  agoraphobia                    and 7                                                    Secondary outcome: Higher proportion of panic-free\            
                                                                                          patients in paroxetine-CBT group.                              

  Panic disorder with/without\   12 weeks fluvoxamine or placebo with or without\         All groups except placebo without CBT improved.\               ([@R461])
  agoraphobia                    CBT                                                      No difference within other groups.                             

  Panic disorder with/without\   12 weeks of sertraline or placebo treatment plus\        Reduced anticipatory anxiety in sertraline plus\               ([@R260])
  agoraphobia                    self-administered CBT or no CBT                          self-administered CBT\                                         
                                                                                          No significant improvements in CGI.                            

  Social anxiety disorder        24 weeks of sertraline/placebo with or without\          All groups improved (also placebo without CBT)\                ([@R34])
                                 exposure therapy (8 sessions in the first 12 weeks of\   Sertraline treatment (without CBT) showed higher\              
                                 treatment)                                               improvement than CBT groups (placebo or sertraline).\          
                                                                                          Placebo without CBT showed lowest benefits.                    

  Social anxiety disorder        Follow-up study of ([@R34])\                             Exposure therapy alone (without placebo or sertraline)\        ([@R197])
                                 Assessment of long-term effects 28 weeks after\          showed a further improvement in CAPS 28 weeks after\           
                                 cessation of medical treatment                           treatment cessation, however only reached improvement\         
                                                                                          levels comparable with those of the sertraline alone group\    
                                                                                          after the initial 24 weeks                                     

                                                                                          CAPS score in the other groups (Exposure + placebo or\         
                                                                                          sertraline and placebo alone) stayed constant (no\             
                                                                                          improvement compared to 24 week CAPS score)                    

  Social anxiety disorder        14 weeks of fluoxetine or placebo plus weekly CBT or\    All treatments were superior to placebo (without CBT) but\     ([@R92])
                                 no CBT\                                                  no differences between groups themselves                       
                                 CBT consisted of group treatment combining in vivo\                                                                     
                                 exposure, cognitive restructuring and social skills\                                                                    
                                 training                                                                                                                

  PTSD                           10 exposure therapy sessions\                            Greater CAPS improvement in paroxetine group vs\               ([@R455])
                                 (1×/week) plus paroxetine CR\                            placebo after 10 weeks\                                        
                                 Optional 12 weeks of maintenance treatment               Higher rate of remission (61.5% vs 23.1% in placebo group)\    
                                                                                          after 10 weeks\                                                
                                                                                          No changes after additional 12 weeks. CAVE drop-out of\        
                                                                                          remitters.                                                     
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------

CR...controlled release.

###### 

Dopaminergic signaling in fear extinction (preclinical studies).

  Drug/manipulation             Extinction training                                                   Extinction retrieval                        Longterm extinction                                    Route       Reference
  ----------------------------- --------------------------------------------------------------------- ------------------------------------------- ------------------------------------------------------ ----------- -----------
  *Facilitating DA signaling*                                                                                                                                                                                        
  L-DOPA                        ns                                                                    \+[1](#TFN16){ref-type="table-fn"}          \+ (SR, Re-in[2](#TFN17){ref-type="table-fn"}, Ren-A   ip          ([@R185])
  Amphetamine                   −                                                                     ns                                          ns                                                     ip          ([@R39])
                                No effect                                                             ns                                          ns                                                     ip          ([@R64])
                                (+)[3](#TFN18){ref-type="table-fn"}                                                                               ns                                                     ip          ([@R364])
  Cocaine                       −                                                                     ns                                          ns                                                     ip          ([@R39])
  Methyl-phenidate              \+                                                                    (+)                                         ns                                                     ip          ([@R2])
                                ns                                                                    \+[1](#TFN16){ref-type="table-fn"}          ns                                                     ip          ([@R2])
  SKF38393 (pAg D1)             −                                                                     ns                                          ns                                                     ip          ([@R39])
                                \+[\*](#TFN23){ref-type="table-fn"}[4](#TFN19){ref-type="table-fn"}   ns                                          ns                                                     ip          ([@R120])
                                ns                                                                    \+[1](#TFN16){ref-type="table-fn"}          ns                                                     CA1         ([@R138])
                                ns                                                                    No effect[1](#TFN16){ref-type="table-fn"}   ns                                                     BLA         ([@R138])
                                ns                                                                    No effect[1](#TFN16){ref-type="table-fn"}   ns                                                     IL          ([@R138])
                                ns                                                                    \+[6](#TFN21){ref-type="table-fn"}          ns                                                     ip          ([@R432])
                                ns                                                                    −[7](#TFN22){ref-type="table-fn"}           ns                                                     ip          ([@R432])
  Quinpirole (D2 ag)            ns                                                                    −                                           ns                                                     ip          ([@R416])
                                ns                                                                    −                                           ns                                                     ip          ([@R369])
                                −[4](#TFN19){ref-type="table-fn"}                                     ns                                          ns                                                     ip          ([@R120])
  *Inhibiting DA signaling*                                                                                                                                                                                          
  6-OH DOPA                     −                                                                     ns                                          ns                                                     mPFC        ([@R361])
                                −                                                                     (−)                                         ns                                                     mPFC        ([@R136])
  D1 knock-out                  −                                                                     ns                                          ns                                                     global KO   ([@R127])
  SCH23390 (D1 ant)             ns                                                                    No effect[1](#TFN16){ref-type="table-fn"}   ns                                                     IL          ([@R138])
                                −                                                                     No effect                                   ns                                                     BLA         ([@R210])
                                No effect                                                             −                                           ns                                                     IL          ([@R210])
                                ns                                                                    −[1](#TFN16){ref-type="table-fn"}           ns                                                     CA1         ([@R138])
                                ns                                                                    No effect[1](#TFN16){ref-type="table-fn"}   ns                                                     BLA         ([@R138])
  Sulpiride (D2 ant)            −                                                                     ns                                          ns                                                     ip          ([@R120])
                                ns                                                                    \+                                          ns                                                     ip          ([@R416])
                                No effect                                                             No effect                                   ns                                                     ip          ([@R362])
  Raclopride (D2 ant)           (−)                                                                   No effect                                   ns                                                     ip          ([@R362])
                                No effect                                                             −                                           ns                                                     IL          ([@R362])
  Haloperidol (D2/D3 ant)       −                                                                     ns                                          ns                                                     ip          ([@R225])
                                (−)                                                                   ns                                          ns                                                     icv         ([@R225])
                                (−)                                                                   −                                           ns                                                     NAcb        ([@R225])
  L-741,741 (D4 ant)            No effect                                                             −                                           ns                                                     mPFC        ([@R411])

Drug administration following extinction training,

37 days,

increased locomotion,

passive avoidance paradigm,

reduced locomotion with 0.3 mg/kg, no effect on locomotion, extinction training and retrieval with 0.1 mg/kg,

rescued impaired extinction retrieval in estrus/metestrus/diestrus,

impairs extinction retrieval in proestrus.

Facilitates rescue of impaired fear extinction;

reduced fear expression at the beginning of extinction training;

enhanced fear expression at the beginning of extinction training.

+, Improved; -, impaired; (+) or (−), only minor effects; ip, intraperitoneal injection; ns, not studied; BLA, intra-basolateral amygdala administration; IL, infralimbic cortex; mPFC, medial prefrontal cortex; CA1, cornu ammonis 1; NAcb, nucleus accumbens; Ren-A, Fear renewal in conditioning context; SR, spontaneous recovery; Re-in, reinstatement; ag, agonist; ant, antagonist, KO, knock-out;

###### 

Human trials: dopaminergic enhancers combined with CBT.

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------
  Disorder                      Study design                                                  Outcome (compared to placebo control group)             Reference
  ----------------------------- ------------------------------------------------------------- ------------------------------------------------------- -----------
  Healthy volunteers            Fear conditioning paradigm, L-DOPA po following\              Protection from renewal (skin conductance responses)    ([@R185])
                                extinction training                                                                                                   

  PTSD (treatment-refractory)   2 single oral MDMA prior to 8h therapy session (3--5 weeks\   MDMA augmented CBT in comparison to placebo (83%\       ([@R354])
                                apart, patients also received therapy prior to first MDMA\    vs 25% response)\                                       
                                exposure as well as between and in follow-up)                 (2 month follow-up); open-label MDMA use offered to\    
                                                                                              patients from the placebo group after last assessment   

  PTSD (treatment-refractory)   Follow-up study from ([@R354])                                MDMA augmented CBT produced long-lasting effects\       ([@R355])
                                                                                              (17--74 months)                                         
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------

###### 

Noradrenergic (NE) signaling in fear extinction (preclinical studies).

  Drug/manipulation                                      Extinction learning                                                   Extinction retrieval                        Longterm extinction                       Route             Reference
  ------------------------------------------------------ --------------------------------------------------------------------- ------------------------------------------- ----------------------------------------- ----------------- -----------
  *Enhancing noradrenergic signaling*                                                                                                                                                                                                  
  Noradrenaline                                          ns                                                                    \+                                          ns                                        icv               ([@R343])
  Methylphenidate                                        \+                                                                    \+                                          ns                                        ip                ([@R2])
  Noradrenaline                                          ns                                                                    \+[1](#TFN27){ref-type="table-fn"}          ns                                        BLA               ([@R30])
                                                         ns                                                                    No effect[1](#TFN27){ref-type="table-fn"}   ns                                        BLA               ([@R138])
                                                         ns                                                                    No effect[1](#TFN27){ref-type="table-fn"}   ns                                        CA1               ([@R138])
                                                         ns                                                                    −[1](#TFN27){ref-type="table-fn"}           ns                                        IL                ([@R138])
  Atomoxetine (NE reuptake inhibitor)                    ns                                                                    No effect[6](#TFN32){ref-type="table-fn"}   \+ (SR)[5](#TFN31){ref-type="table-fn"}   systemic          ([@R236])
  Isoproterenol (β ag)                                   No effect                                                             ns                                          ns                                        ip (subchronic)   ([@R117])
                                                         ns                                                                    (+)[1](#TFN27){ref-type="table-fn"}         ns                                        ip (subchronic)   ([@R117])
                                                         ns                                                                    (+)[1](#TFN27){ref-type="table-fn"}         ns                                        mPFC              ([@R117])
  Yohimbine (α2 ant)[8](#TFN34){ref-type="table-fn"}     \+                                                                    ns                                          ns                                        sc                ([@R56])
                                                         ns                                                                    No effect[1](#TFN27){ref-type="table-fn"}   ns                                        sc                ([@R56])
                                                         \+[\#](#TFN38){ref-type="table-fn"}[2](#TFN28){ref-type="table-fn"}   \+[2](#TFN28){ref-type="table-fn"}          ns                                        sc                ([@R56])
                                                         \+                                                                    \+                                          −                                         ip                ([@R359])
                                                         No effect[7](#TFN33){ref-type="table-fn"}                             No effect                                   ns                                        ip                ([@R364])
                                                         ns                                                                    \+[\*](#TFN35){ref-type="table-fn"}         ns                                        ip                ([@R200])
                                                         ns                                                                    No effect[6](#TFN32){ref-type="table-fn"}   \+ (SR)[5](#TFN31){ref-type="table-fn"}   systemic          ([@R236])
  Atipamezole (α2 ant)[8](#TFN34){ref-type="table-fn"}   ns                                                                    No effect[4](#TFN30){ref-type="table-fn"}   ns                                        sc                ([@R95])
  *Inhibiting noradrenergic signaling*                                                                                                                                                                                                 
  Prazosine (α1 ant)                                     ns                                                                    No effect[1](#TFN27){ref-type="table-fn"}   ns                                        ip (subchronic)   ([@R116])
                                                         −                                                                     ns                                          ns                                        ip (subchronic)   ([@R116])
                                                         −                                                                     ns                                          ns                                        intra-mPFC        ([@R116])
  Propanolol (β ant)                                     No effect                                                             ns                                          ns                                        sc                ([@R56])
                                                         ns                                                                    No effect[1](#TFN27){ref-type="table-fn"}   ns                                        sc                ([@R56])
                                                         No effect[2](#TFN28){ref-type="table-fn"}                             (−)[3](#TFN29){ref-type="table-fn"}         ns                                        sc                ([@R56])
                                                         (+)[\#](#TFN38){ref-type="table-fn"}                                  No effect                                   ns                                        ip                ([@R437])
                                                         −                                                                     −                                           ns                                        ip (subchronic)   ([@R117])
                                                         ns                                                                    No effect[1](#TFN27){ref-type="table-fn"}   ns                                        ip (subchronic)   ([@R117])
  Atenolol (β ant)                                       −                                                                     ns                                          ns                                        mPFC              ([@R117])
                                                         ns                                                                    No effect[1](#TFN27){ref-type="table-fn"}   ns                                        mPFC              ([@R117])
  Sotalol (β ant)                                        No effect                                                             No effect                                   ns                                        ip                ([@R437])
  Timolol (β ant)                                        ns                                                                    \+[1](#TFN27){ref-type="table-fn"}          ns                                        BLA               ([@R138])
  Propanolol (β ant)                                     No effect                                                             −                                           ns                                        IL                ([@R365])
                                                         ns                                                                    No effect[1](#TFN27){ref-type="table-fn"}   ns                                        IL                ([@R365])
  Timolol (β ant)                                        ns                                                                    \+[1](#TFN27){ref-type="table-fn"}          ns                                        IL                ([@R138])
                                                         ns                                                                    No effect[1](#TFN27){ref-type="table-fn"}   ns                                        CA1               ([@R138])

Drug administration following extinction training;

spaced CS extinction, US = 0.7mA;

spaced CS extinction when US = 0.4mA; no effect when US = 0.7mA,

cocaine-conditioned place preference,

4 weeks,

instrumental lever press response,

reduced fear expression at start of extinction training, if extinction is performed in the same context as conditioning,

note that the net effect of α2 blockade is enhancement of noradrenergic signaling (see text).

Facilitates rescue of impaired fear extinction;

facilitates extinction of remote memories,

only in older animals (7 months), younger ones (2 months) are not affected

reduced fear expression at the beginning of extinction training.

+, Improved; -, impaired; (+) or (−), only minor effects; ip, intraperitoneal injection; injection; sc, subcutanous injection; icv, intracerebroventricular injection; ns, not studied; HPC, intra-hippocampal administration; BLA, intra-basolateral amygdala administration; IL, infralimbic cortex; PL, prelimbic cortex; CA1, cornu ammonis 1; Ren, Fear renewal; SR, spontaneous recovery; Re-in, reinstatement; ag, agonist; ant, antagonist, KO, knock-out; \# reduced fear expression at start of extinction training.

###### 

Yohimbine combined with CBT in small-scale clinical trials.

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Disorder                        Study design                                                                                 Outcome (compared to placebo control group)                               Reference
  ------------------------------- -------------------------------------------------------------------------------------------- ------------------------------------------------------------------------- -----------
  Social anxiety disorder (SAD)   4 sessions consisting of yohimbine being administered\                                       Yohimbine augmented CBT-induced improvement in\                           ([@R476])
                                  prior to a CBT [a](#TFN41){ref-type="table-fn"} session                                      SAD (self-report measures; 21 day follow-up)                              

  Claustrophobic fear             1 single oral yohimbine dose prior to an exposure [b](#TFN42){ref-type="table-fn"} session   Yohimbine augment CBT-induced reduced fear of\                            ([@R419])
                                                                                                                               enclosed spaces (7 day follow-up)                                         

  Fear of flying                  2 single oral yohimbine prior to VRET session                                                No fear augmenting effect of yohimbine [c](#TFN43){ref-type="table-fn"}   ([@R345])
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

VRET, virtual reality exposure.

CBT involved an oral presentation on challenging topics in front of the therapists, other group members, and confederates,

behavioral approach task,

Lack of yohimbine effect might possibly have been due to the powerful influence of VRET exposure itself leading to a greater impact on the results from this than from the manipulation (drug condition) that 'washed out' or overrode any effect of manipulation ([@R345]),

###### 

Glutamatergic signaling in fear extinction (preclinical studies).

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Drug/manipulation                      Extinction\                                  Extinction\                                                           Longterm\        Route      Reference
                                         training                                     retrieval                                                             extinction                  
  -------------------------------------- -------------------------------------------- --------------------------------------------------------------------- ---------------- ---------- ---------------------------------
  *Facilitating AMPA signaling*                                                                                                                                                         

  PEPA (AMPA potentiator)                No effect[\*](#TFN49){ref-type="table-fn"}   No effect[\*](#TFN49){ref-type="table-fn"}                            ns               ip         ([@R536])

                                         No effect[\*](#TFN49){ref-type="table-fn"}   \+[\*](#TFN49){ref-type="table-fn"}                                   ns               ip         ([@R548])

                                         \+[\#](#TFN50){ref-type="table-fn"}          \+                                                                    \+ (Re-in)       ip         ([@R549])

                                         \+                                           \+                                                                    ns               ip         ([@R567])

  PEPA + NBQX (AMPA ant)                 No effect                                    No effect                                                             ns               ip         ([@R567])

  PEPA (AMPA potentiator)                (+)                                          (+)                                                                   ns               PL         ([@R567])

                                         \+                                           \+                                                                    ns               BLA/ceA    ([@R567])

  *Inhibiting AMPA signaling*                                                                                                                                                           

  CNQX (AMPA ant)                        ns                                           No effect                                                             ns               BLA        ([@R130]; [@R300]; [@R565])

  *Facilitating NMDA signaling*                                                                                                                                                         

  D-Cycloserine                          ns                                           \+                                                                    ns               ip         ([@R526])

                                         ns                                           \+[1](#TFN44){ref-type="table-fn"}                                    ns               Systemic   ([@R281])

                                         ns                                           \+[1](#TFN44){ref-type="table-fn"}                                    \+ (Re-in)       Systemic   ([@R282])

                                         ns                                           \+[1](#TFN44){ref-type="table-fn"}                                    ns               Systemic   ([@R283])

                                         ns                                           \+[1](#TFN44){ref-type="table-fn"}                                    ns               ip         ([@R402])

                                         ns                                           \+                                                                    ns               ip         ([@R553])

                                         ns                                           \+                                                                    ns               ip         ([@R287])

                                         ns                                           \+                                                                    No effect        sc         ([@R543])

                                         ns                                           \+                                                                    ns               sc         ([@R533])

                                         ns                                           \+                                                                    ns               Systemic   ([@R529])

                                         ns                                           \+                                                                    ns               ip         ([@R552])

                                         ns                                           \+                                                                    ns               ip         ([@R552])

                                         ns                                           \+                                                                    ns               ip         ([@R200])

                                         ns                                           \+                                                                    ns               po         ([@R550])

                                         ns                                           \+                                                                    ns               ip         ([@R327])

                                         \+                                           \+                                                                    ns               ip         ([@R470])

                                         ns                                           \+                                                                    ns               sc         ([@R272])

                                         ns                                           \+                                                                    No effect        sc         ([@R41])

                                         ns                                           \+                                                                    ns               ip         ([@R298])

                                         \+[\#](#TFN50){ref-type="table-fn"}          \+                                                                    \+ (Re-in)       ip         ([@R549])

                                         \+                                           ns                                                                    ns               ip         ([@R289])

                                         ns                                           \+[1](#TFN44){ref-type="table-fn"}                                    ns               Systemic   ([@R273])

                                         No effect[\*](#TFN49){ref-type="table-fn"}   \+[\*](#TFN49){ref-type="table-fn"}                                   ns               ip         ([@R548])

                                         No effect                                    \+                                                                    ns               ip         ([@R515])

                                         ns                                           \+[1](#TFN44){ref-type="table-fn"}                                    ns               ip         ([@R515])

                                         ns                                           \+                                                                    ns               Systemic   ([@R181])

                                         ns                                           \+                                                                    ns               ip         ([@R325])

                                         \+                                           \+                                                                    ns               ip         ([@R20])

                                         ns                                           \+[1](#TFN44){ref-type="table-fn"}[\*](#TFN49){ref-type="table-fn"}   ns               ip         ([@R536])

                                         ns                                           \+                                                                    ns               BLA        ([@R526])

                                         ns                                           \+[1](#TFN44){ref-type="table-fn"}                                    ns               BLA        ([@R281])

                                         ns                                           \+                                                                    ns               BLA        ([@R287])

                                         ns                                           \+                                                                    ns               BLA        ([@R317])

                                         ns                                           \+                                                                    ns               BLA        ([@R287])

                                         ns                                           \+                                                                    ns               BLA        ([@R8])

                                         ns                                           No effect                                                             ns               BLA        ([@R36])

                                         ns                                           \+                                                                    ns               HPC        ([@R36])

                                         ns                                           \+                                                                    ns               HPC        ([@R429])

  Spermidine                             ns                                           \+[1](#TFN44){ref-type="table-fn"}                                    ns               HPC        ([@R160])

  *Inhibiting NMDA signaling*                                                                                                                                                           

  MK-801 (non-competitive NMDA ant)      ns                                           −                                                                     ns               Systemic   ([@R21]); ([@R491])

                                         ns                                           ns                                                                    \+ (Re-in)       sc         ([@R238])

                                         ns                                           −[1](#TFN44){ref-type="table-fn"}                                     ns               ip         ([@R287]); ([@R302])

                                         ns                                           −                                                                     ns               Systemic   ([@R271]); ([@R69])

  CPP (competitive NMDA ant)             No effect                                    −[5](#TFN48){ref-type="table-fn"}                                     ns               ip         ([@R451]); ([@R483])

                                         No effect                                    −                                                                     ns               mPFC       ([@R51])

                                         ns                                           −[1](#TFN44){ref-type="table-fn"}                                     ns               mPFC       ([@R51])

                                         −                                            −                                                                     ns               BLA        ([@R403])

  AP-5 (competitive NMDA ant)            ns                                           −                                                                     ns               BLA        ([@R130])

                                         −[\#\#](#TFN51){ref-type="table-fn"}         −                                                                     ns               BLA        ([@R285])

                                         ns                                           −[1](#TFN44){ref-type="table-fn"}                                     ns               BLA        ([@R296]); ([@R276]); ([@R138])

                                         No effect                                    −                                                                     ns               BLA        ([@R296]); ([@R565])

                                         ns                                           −                                                                     ns               CA1        ([@R500])

                                         ns                                           −[1](#TFN44){ref-type="table-fn"}                                     ns               CA1        ([@R138])

                                         ns                                           −[1](#TFN44){ref-type="table-fn"}                                     ns               mPFC       ([@R138])

  *Inhibiting NMDA signaling*                                                                                                                                                           

  ifenprodil (non-comp NR2B--NMDA ant)   −                                            −                                                                     ns               ip         ([@R483])

                                         ns                                           −[1](#TFN44){ref-type="table-fn"}                                     ns               Systemic   ([@R484])

                                         −                                            −                                                                     ns               BLA        ([@R483]); ([@R277]);\
                                                                                                                                                                                        ([@R276])

                                         ns                                           No effect[1](#TFN44){ref-type="table-fn"}                             ns               BLA        ([@R276]); ([@R277]); ([@R484])

                                         No effect                                    −                                                                     ns               mPFC       ([@R277])

                                         No effect                                    No effect                                                             ns               mPFC       ([@R484])

                                         No effect                                    −[1](#TFN44){ref-type="table-fn"}                                     ns               mPFC       ([@R277]); ([@R484])

                                         ns                                           −[1](#TFN44){ref-type="table-fn"}                                     ns               HPC        ([@R160])

  Ro25--6981 (non-comp NR2B--NMDA ant)   −                                            No effect                                                             ns               ip         ([@R89], [@R90])

  *Facilitating mGluR signaling*                                                                                                                                                        

  CDPPB (mGluR5 pos modulator)           \+[3](#TFN46){ref-type="table-fn"}           ns                                                                    ns               sc         ([@R153])

  AMN082 (mGluR7 ag)                     \+[\*](#TFN49){ref-type="table-fn"}          \+[\*](#TFN49){ref-type="table-fn"}                                   ns               ip         ([@R536])

                                         ns                                           \+                                                                    ns               po         ([@R135])

                                         −                                            No effect                                                             ns               ip         ([@R515])

                                         ns                                           −[1](#TFN44){ref-type="table-fn"}                                     ns               ip         ([@R515])

                                         (+)                                          No effect                                                             ns               BLA        ([@R114])

                                         −                                            −                                                                     ns               mPFC       ([@R358])

  *Inhibiting mGluR signaling*                                                                                                                                                          

  CPCCOEt (non-comp mGluR1 ant)          −                                            −                                                                     ns               BLA        ([@R248])

                                         No effect                                    No effect                                                             No effect (SR)   ip         ([@R316])

  mGluR4 KO                              ns                                           \+                                                                    ns               No drug    ([@R94])

  mGluR5 KO                              −                                            −                                                                     ns               No drug    ([@R547])

  MTEP (mGluR5 ant)                      No effect                                    −                                                                     − (SR)           ip         ([@R316])

                                         ns                                           ns                                                                    − (SR)           BLA        ([@R316])

  MPEP (allosteric mGluR5 ant)           No effect                                    No effect                                                             ns               ip         ([@R515])

                                         ns                                           No effect[1](#TFN44){ref-type="table-fn"}                             ns               ip         ([@R515])

                                         No effect                                    −                                                                     ns               ip         ([@R144])

                                         No effect                                    −                                                                     ns               IL         ([@R144])

                                         −                                            −                                                                     ns               IL         ([@R460])

  mGluR7 KO                              −[4](#TFN47){ref-type="table-fn"}            ns                                                                    ns               No drug    ([@R58]);\
                                                                                                                                                                                        ([@R157])

                                         \+                                           \+                                                                    ns               No drug    ([@R134])

  siRNA knock-down of mGluR7             −[2](#TFN45){ref-type="table-fn"}            ns                                                                    ns               No drug    ([@R135])

  mGluR8 KO                              No effect[\#](#TFN50){ref-type="table-fn"}   No effect                                                             ns               No drug    ([@R134])

  (S)-3,4-DCPG (mGluR8 ag)               −                                            No effect                                                             ns               BLA        ([@R114])
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Drug administration following extinction training;

conditioned taste aversion;

cocaine conditioned place preference;

food-rewarded operant conditioning,

reduced locomotion.

Facilitates rescue of impaired fear extinction;

reduced fear expression at the beginning of extinction training;

enhanced fear expression at the beginning of extinction training.

+, Improved; -, impaired; (+) or (−), only minor effects; po, peroral administration; ip, intraperitoneal injection; sc, subcutaneous injection; ns, not studied; BLA, intra-basolateral amygdala administration; HPC, hippocampus; IL, infralimbic cortex; SR, spontaneous recovery; Re-in, reinstatement; ag, agonist; ant, antagonist, KO, knock-out;

###### 

Human trials: D-cycloserine (DCS) combined with CBT.

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Disorder                          Study design                                              Outcome (compared to placebo control group)                 Reference
  --------------------------------- --------------------------------------------------------- ----------------------------------------------------------- ---------------------
  Healthy volunteers                DCS or placebo 2--3 h prior extinction training           No effect on fear extinction or fear recovery in healthy\   ([@R173])
                                                                                              volunteers                                                  

  Healthy volunteers                DCS, placebo, valproic acid or combination of DCS\        Administration of DCS, valproic acid or DCS/valproic\       ([@R264])
                                    and valproic acid 1.5 h prior extinction training         acid combination facilitates fear extinction and\           
                                                                                              protects from reinstatement                                 

  Healthy volunteers                DCS or placebo 2 h prior extinction training              No effect on extinction learning and retention in\          ([@R253])
                                                                                              healthy volunteers                                          

  Acrophobia                        DCS or placebo 1 h prior 2 sessions of virtual reality\   Reduced fear symptoms in DCS group at all timepoints        ([@R430])
                                    exposure\                                                                                                             
                                    3 month follow-up                                                                                                     

  Acrophobia                        2 sessions virtual reality exposure plus DCS or\          No advantage of DCS over placebo augmented VRE\             ([@R505]) ([@R475])
                                    placebo [after]{.ul} the sessions\                        DCS effect depends on success of exposure sessions\         
                                    1 month follow-up\                                        (within-session fear reduction)                             
                                    Re-evaulation of ([@R505])                                                                                            

  Snake phobia                      DCS or placebo 1 h prior a single exposure session        Same level of improvement with DCS, but DCS group\          ([@R371])
                                                                                              achieved fear reduction quicker                             

  Panic disorder                    DCS or placebo 1 h prior CBT session 3--5\                DCS group showed greater reduction in panic\                ([@R390])
                                    1 month follow-up                                         symptom severity at all timepoints                          

  Panic disorder with agoraphobia   DCS or placebo 1 h prior 3 individual exposure\           No benefits of DCS at all timepoints, but initial\          ([@R467])
                                    sessions + 8 group CBT sessions 5 months\                 benefical effects in severely symptomatic patients?         
                                    follow-up                                                                                                             

  PTSD                              DCS or placebo 1 h prior 10 weekly exposure\              No overall enhancement of treatment effects.\               ([@R101])
                                    sessions                                                  Higher symptom reduction in severe cases.                   

  PTSD\                             DCS or placebo 30 min prior exposure session 2--6         Weaker symptom reduction compared to placebo\               ([@R301])
  (combat-related)                                                                            group                                                       

  PTSD                              DCS or placebo 1.5 h prior 12 weekly VRE session 6\       DCS group showed earlier and greater improvement as\        ([@R112])
                                    months follow-up                                          well as higher remission rates                              

  pediatric PTSD                    DCS or placebo 12 1 h prior session 5--12                 No difference in symptom reduction, DCS group\              ([@R452])
                                                                                              showed trend for faster response and better retention\      
                                                                                              in 3 month follow-up                                        

  SAD                               1× psychoeducation; DCS or placebo 1 h prior to 4 h\      Decreased self-reported social anxiety symptoms in\         ([@R216])
                                    exposure session (5×, individual or group)\               DCS group after 1 month                                     
                                    1 month follow-up                                                                                                     

  SAD                               DCS or placebo 1 h prior to 4 h exposure therapy\         Fewer social fear and avoidance in DCS group.\              ([@R174])
                                    (5×)                                                      Significant differences in DCS vs placebo following 3rd\    
                                                                                              exposure session.                                           

  SAD                               DCS or placebo with CBT                                   Greater overall rates of improvement and lower\             ([@R477])
                                                                                              post-treatment severity                                     

  SAD                               12 weeks; DCS or placebo 1h prior 5 exposure\             Similar response and remission rates, DCS group\            ([@R219])
                                    sessions (12 sessions at all); 6-months follow-up         improved quicker                                            

  OCD                               D-Cycloserine (DCS) or placebo 4 h prior each\            No statistically significant difference.\                   ([@R489])
                                    exposure session, 12 weeks (one exposure\                 High response rates in treatment and placebo group.         
                                    session/week)                                                                                                         

  OCD                               2×/week DCS or placebo 2 h prior exposure and\            Faster improvements in DCS group\                           ([@R265])
                                    response prevention (ERP) sessions\                       No difference between DCS and placebo group\                
                                    (max 10)\                                                 (no further benefit).                                       
                                    3 months follow-up                                                                                                    

  OCD                               2×/week DCS or placebo 1 h prior 10 ERP sessions\         Faster improvements in DCS group\                           ([@R538])\
                                    1 month follow-up\                                        No difference between DCS and placebo group\                ([@R70])
                                    Re-evaluation of [@R538]                                  (no further benefit).\                                      
                                                                                              Specific improvements of DCS in the first 5 sessions,\      
                                                                                              6× faster than placebo group                                

  Pediatric OCD                     DCS or placebo 1 h prior weekly session 4--10\            Modest reduction of obsessive symptoms                      ([@R490])
                                    (psychoeduction, cognitive training and ERP) for 10\                                                                  
                                    wks                                                                                                                   

  Pediatric OCD                     DCS or placebo 1 h prior session 5--9 ERP-CBT             Significant improvements in OCD severity from\              ([@R131])
                                                                                              posttreatment to 1-month follow-up in severe and\           
                                                                                              difficult-to-treat pediatric OCD                            

  Pediatric OCD                     DCS or placebo immediately after each of 10 CBT\          both groups improved;\                                      ([@R324])
                                    (ERP) sessions\                                           no significant advantage of DCS at any timepoint            
                                    1 year follow-up                                                                                                      
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------

###### 

GABAergic signaling in fear extinction (preclinical studies).

  *Facilitating GABA signaling*                                                                                                                                                                                                                             
  ----------------------------------------------------- ---------------------------------------------------------------------- --------------------------------------------------------------------- -------------------------------------------- --------- -------------------------------
  *GABA~A~ agonists GABA-binding site (αβ interface)*                                                                                                                                                                                                       
  Muscimol                                              \+[\#](#TFN61){ref-type="table-fn"}                                    No effect                                                             ns                                           BLA       ([@R7])
                                                        ns                                                                     \+[1](#TFN53){ref-type="table-fn"},[7](#TFN59){ref-type="table-fn"}   ns                                           BLA       ([@R7])
                                                        −[\#](#TFN61){ref-type="table-fn"}                                     −                                                                     ns                                           BLA       ([@R276]), ([@R277])
                                                        ns                                                                     −[1](#TFN53){ref-type="table-fn"}                                     ns                                           BLA       ([@R277])
                                                        (+)[\#](#TFN61){ref-type="table-fn"}                                   −                                                                     ns                                           BLA       ([@R468])
                                                        −                                                                      −                                                                     ns                                           mPFC      ([@R277])
                                                        ns                                                                     −[1](#TFN53){ref-type="table-fn"}                                     ns                                           mPFC      ([@R277])
                                                        ns                                                                     No effect[1](#TFN53){ref-type="table-fn"}                             ns                                           IL        ([@R7])
                                                        \+[\#](#TFN61){ref-type="table-fn"}                                    (+)                                                                   ns                                           IL        ([@R7])
                                                        −                                                                      −                                                                     ns                                           IL        ([@R468])
                                                        No effect                                                              −                                                                     ns                                           IL        ([@R278])
                                                        (+)[\#](#TFN61){ref-type="table-fn"}                                   No effect                                                             ns                                           PL        (([@R278]); ([@R468]))
                                                        ns                                                                     ns                                                                    \+ (Ren-A)[8](#TFN60){ref-type="table-fn"}   dHPC      ([@R86])
                                                        −                                                                      −                                                                     No effect (Ren-A)                            dHPC      ([@R86])
                                                        (+)[\#](#TFN61){ref-type="table-fn"}                                   −                                                                     ns                                           vHPC      ([@R468])
  *GABA~A~: agonists BZD-binding site αγ interface)*                                                                                                                                                                                                        
  Chlordiazepoxide                                      −                                                                      ns                                                                    ns                                           ip        ([@R159])
                                                        ns                                                                     −                                                                     ns                                           ip        ([@R40])
  Diazepam                                              ns                                                                     −                                                                     ns                                           ip        ([@R407])
                                                        ns                                                                     −                                                                     ns                                           ip        ([@R40])
  Midazolam                                             ns                                                                     −[1](#TFN53){ref-type="table-fn"}                                     ns                                           ip        ([@R54])
                                                        −[\#\#](#TFN62){ref-type="table-fn"}[6](#TFN58){ref-type="table-fn"}   −                                                                     ns                                           ip        ([@R191], [@R192]), ([@R193])
                                                        −[\#](#TFN61){ref-type="table-fn"}[6](#TFN58){ref-type="table-fn"}     −                                                                     ns                                           BLA       ([@R191], [@R192], [@R193])
  *GABA~B~ receptor agonists*                                                                                                                                                                                                                               
  Baclofen                                              ns                                                                     −                                                                     ns                                           ip        ([@R199])
  GS39783 (positive modulator GABA~B~)                  ns                                                                     No effect                                                             ns                                           po        ([@R499])
  *Inhibiting GABA signaling*                                                                                                                                                                                                                               
  Drug/manipulation                                     Extinction learning                                                    Extinction retrieval                                                  Longterm extinction                          Route     Reference
                                                                                                                                                                                                                                                            
  GAD67 KD in BLA                                       −                                                                      ns                                                                    ns                                           No drug   ([@R202])
  GAD65 KO                                              −[2](#TFN54){ref-type="table-fn"}                                      −[2](#TFN54){ref-type="table-fn"}                                     ns                                           No drug   ([@R449])
  α5 KD in HPC                                          ns                                                                     −[3](#TFN55){ref-type="table-fn"}                                     ns                                           No drug   ([@R556])
  α1 KO in CRF+ cells                                   −                                                                      −                                                                     ns                                           No drug   ([@R149])
  Picrotoxin                                            ns                                                                     \+                                                                    ns                                           ip        ([@R330])
                                                        ns                                                                     \+[4](#TFN56){ref-type="table-fn"}                                    ns                                           IL        ([@R510])
                                                        ns                                                                     \+[4](#TFN56){ref-type="table-fn"}                                    ns                                           PL        ([@R510])
                                                        ns                                                                     +\*                                                                   ns                                                     ([@R142])
  Bicuculline                                           ns                                                                     \+[1](#TFN53){ref-type="table-fn"}                                    ns                                           BLA       ([@R30])
  Bicuculline + propanolol                              ns                                                                     No effect[1](#TFN53){ref-type="table-fn"}                             ns                                           BLA       ([@R30])
  FG7142                                                −                                                                      −                                                                     ns                                           ip        ([@R189])
                                                        ns                                                                     −                                                                     ns                                           ip        ([@R249], [@R250])
  *GABA~B~ receptor antagonism*                                                                                                                                                                                                                             
  GABA~B(1b)~ KO                                        −[5](#TFN57){ref-type="table-fn"}                                      ns                                                                    ns                                           No drug   ([@R235])
  Phaclofen                                             ns                                                                     No effect                                                             ns                                           ip        ([@R199])
  CGP52432                                              ns                                                                     No effect                                                             ns                                           po        ([@R499])

Drug administration following extinction training;

only cued memory, contextual intact,

trace conditioning,

reconsolidation (injection prior reactivation of memory),

conditioned taste aversion,

midazolam may not impair fear extinction if initial extinction occurs drug-free \[see ([@R193])\],

short extinction training (5 CS presentations),

injection prior renewal-testing.

Reduced fear expression at start of extinction training;

enhanced immobility at start of extinction training;

+, Improved; -, impaired; (+) or (−), only minor effects; ip, intraperitoneal injection; po, peroral administration; ns, not studied; HPC, intra-hippocampal administration; BLA, intra-basolateral amygdala administration; IL, infralimbic cortex; PL, prelimbic cortex; Ren-A, Fear renewal in conditioning context; ag, agonist; ant, antagonist, KO, knock-out;

###### 

Cannabinoid signaling in fear extinction (preclinical studies).

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  *Enhanced cannabinoid signaling*                                                                                                                                                                         
  -------------------------------------- -------------------------------------- ------------------------------------------- ------------------------------------------------------- ---------------------- -------------------------
  Cannabidiol                            \+                                     \+                                          ns                                                      icv                    ([@R33])

                                         \+                                     \+                                          ns                                                      IL                     ([@R113])

  Anandamide                             ns                                     \+[1](#TFN64){ref-type="table-fn"}          ns                                                      dCA1                   ([@R102])

  AM404 (eCB uptake inhibitor)           ns                                     \+                                          ns                                                      ip                     ([@R393])

                                         ns                                     \+                                          \+ (Re-in)                                              ip                     ([@R75])

                                         \+                                     (+)                                         ns                                                      icv                    ([@R33])

                                         No training                            \+                                          ns                                                      IL                     ([@R297])

  AM3506 (FAAH inhibitor)                ns                                     \+                                          ns                                                      ip                     ([@R178])

  WIN 55,212-2 (low-dose CB1 Ag)         \+[\*](#TFN68){ref-type="table-fn"}    No effect[2](#TFN65){ref-type="table-fn"}   ns                                                      ip                     ([@R394])

  WIN 55,212-2 (high-dose CB1 Ag)        (−)[\*](#TFN68){ref-type="table-fn"}   No effect[2](#TFN65){ref-type="table-fn"}   ns                                                      ip                     ([@R394])

  WIN 55,212-2 (CB1 Ag)                  \+[°](#TFN69){ref-type="table-fn"}     \+[°](#TFN69){ref-type="table-fn"}          ns                                                      ip                     ([@R394])

                                         ns                                     \+                                          nd                                                      ip                     ([@R393])

  WIN 55,212-2 (CB1 Ag)                  ns                                     \+[4](#TFN67){ref-type="table-fn"}          ns                                                      BLA                    ([@R151]))

                                         ns                                     \+[4](#TFN67){ref-type="table-fn"}          ns                                                      HPC                    ([@R151])

                                         ns                                     No effect[4](#TFN67){ref-type="table-fn"}   ns                                                      mPFC                   ([@R151])

                                         ns                                     \+                                          No effect (Re-in, SR[3](#TFN66){ref-type="table-fn"})   IL                     ([@R297])

                                         No training                            \+                                          ns                                                      IL                     ([@R297])

                                         ns                                     No effect                                   ns                                                      PL                     ([@R263])

  HU210                                  No training                            \+                                          ns                                                      IL                     ([@R297])

  URB597 (AEA hydrolysis inhibitor)      No training                            \+                                          ns                                                      IL                     ([@R297])

  AM3506 (FAAH inhibitor) + SR141716A\   ns                                     No effect                                   ns                                                      ip + BLA               ([@R178])
  (CB1 ant)                                                                                                                                                                                                

  AM3506 (FAAH inhibitor)                ns                                     \+                                          ns                                                      BLA                    ([@R178])

                                         No training                            No effect                                   ns                                                      BLA                    ([@R178])

  Cannabidiol + SR141716A (CB1 ant)      No effect                              No effect                                   ns                                                      IL + ip                ([@R113])

  *Reduced* cannabinoid signaling                                                                                                                                                                          

  Drug/manipulation                      Extnction\                             Extinction retrieval                        Longterm extinction                                     Administration route   Reference
                                         learning                                                                                                                                                          

                                                                                                                                                                                                           

  CB1 KO                                 −                                      −                                           ns                                                      No drug                ([@R63])

  CB1 KO                                 −                                      ns                                          ns                                                      No drug                (([@R119]); ([@R242]);\
                                                                                                                                                                                                           ([@R322]); ([@R415]))

  D1-CB1 KO                              −                                      ns                                          ns                                                      No drug                ([@R509])

  SR141716A CB1 ant                      ns                                     No effect[1](#TFN64){ref-type="table-fn"}   ns                                                      sc                     ([@R322])

                                         −                                      ns                                          ns                                                      sc, ip                 (([@R242]); ([@R377]);\
                                                                                                                                                                                                           ([@R415])

                                         ns                                     −[1](#TFN64){ref-type="table-fn"}           ns                                                      ip                     ([@R497])

                                         −                                      No effect                                   ns                                                      ip                     ([@R394], [@R393])

                                         ns                                     −                                           ns                                                      ip                     ([@R75])

                                         −[\#\#](#TFN70){ref-type="table-fn"}   No effect                                   ns                                                      ip                     ([@R43])

  AM251 (CB1 inverse ag)                 −                                      ns                                          ns                                                      ip                     ([@R427])

                                         ns                                     −[1](#TFN64){ref-type="table-fn"}           ns                                                      dCA1                   ([@R102])

                                         ns                                     −                                           ns                                                      IL                     ([@R297])

                                         No training                            No effect                                   ns                                                      IL                     ([@R297])

                                         ns                                     −                                           ns                                                      PL                     ([@R263])
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Drug administration following extinction training;

drug-free retrieval of contextual fear memory;

5 days,

single-prolonged-stress model: injection immediately after trauma.

Recent memory;

remote memory;

enhanced immobility at start of extinction training;

+, Improved; -, impaired; (+) or (−), only minor effects; ip, intraperitoneal injection; ip, sc, subcutanous injection; ns, not studied; HPC, intra-hippocampal administration; BLA, intra-basolateral amygdala administration; IL, infralimbic cortex; PL, prelimbic cortex; CA1, cornu ammonis 1; Re-in, reinstatement; SR, spontaneous recovery, ag, agonist; ant, antagonist, KO, knock-out;

###### 

Human trials: cannabinoids combined with CBT.

  --------------------------------------------------------------------------------------------------------------------------------------------------
  Disorder             Study design                                                        Outcome (compared to placebo control group)   Reference
  -------------------- ------------------------------------------------------------------- --------------------------------------------- -----------
  Healthy volunteers   Fear conditioning paradigm, cannabidiol inhalation prior or\        Reduced fear in retrieval\                    ([@R91])
                       following extinction                                                Protection against reinstatement              

  Healthy volunteers   Fear conditioning paradigm, tetrahydrocannabinol prior extinction   No effect                                     ([@R253])

  Healthy volunteers   Fear conditioning paradigm, Dronabinol prior extinction             Reduced fear in retrieval                     ([@R424])
  --------------------------------------------------------------------------------------------------------------------------------------------------

###### 

Neuropeptide signaling in fear extinction (preclinical studies).

  *Neuropeptides*                                                                                                                                                         
  ------------------------ --------------------------------------------------------------------------- ------------------------------------------- ----------- ---------- -----------
  Oxytocin                 −                                                                           ns                                          ns          icv        ([@R514])
                           \+[\#](#TFN79){ref-type="table-fn"}                                         \+                                          ns          DLS        ([@R566])
                           −\*[5](#TFN76){ref-type="table-fn"}                                         −\*[5](#TFN76){ref-type="table-fn"}         ns          ip         ([@R129])
  Chronic oxytocin (30d)   ns                                                                          No effect[6](#TFN77){ref-type="table-fn"}   ns          in         ([@R23])
  NPY                      \+                                                                          \+                                          ns          icv        ([@R183])
  NPY KO                   −[3](#TFN74){ref-type="table-fn"}[\*\*\*](#TFN78){ref-type="table-fn"}      −                                           ns          No drug    ([@R522])
  NPY Y1 KO                −                                                                           No effect                                   ns          No drug    ([@R522])
  NPY Y2KO                 No effect                                                                   No effect                                   ns          No drug    ([@R522])
  NPY Y1/Y2 KO             −                                                                           −                                           ns          No drug    ([@R522])
  Leu31Pro-NPY (Y1 ag)     ns                                                                          \+                                          ns          BLA        ([@R268])
  BIBO 3304 (Y1 ant)       ns                                                                          −                                           ns          BLA        ([@R183])
  NPS                      (+)[4](#TFN75){ref-type="table-fn"}                                         No effect                                   No effect   BLA        ([@R240])
                           \+                                                                          ns                                          ns          icv        ([@R474])
  SHA68 (NPS-R ant)        −)[4](#TFN75){ref-type="table-fn"}, [\*\*\*](#TFN78){ref-type="table-fn"}   −                                           − (Ren-A)   BLA        ([@R240])
  Naloxone                 −                                                                           −                                           ns          Systemic   ([@R338])
                           ns                                                                          No effect[1](#TFN72){ref-type="table-fn"}   ns          Systemic   ([@R338])
                           −                                                                           −                                           ns          vlPAG      ([@R337])
                           −                                                                           −                                           ns          vlPAG      ([@R403])
                           No effect                                                                   No effect                                   ns          BLA        ([@R403])
  CTAP (MOR ant)           −                                                                           −                                           ns          vlPAG      ([@R336])
  Dynorphin KO             −[3](#TFN74){ref-type="table-fn"}                                           −                                           ns          No drug    ([@R31])
  nor-BNI (KOR ant)        ns                                                                          −[1](#TFN72){ref-type="table-fn"}           ns          Systemic   ([@R31])

Drug administration following extinction training;

social fear conditioning;

animals show accelerated fear learning;

administration 2h prior extinction training;

single prolonged stress model;

BTBR mouse autism model and C57BL6J.

Enhanced fear expression at the beginning of extinction training,

reduced fear expression at the beginning of extinction training.

+, Improved; -, impaired; (+) or (−), only minor effects; ip, intraperitoneal injection; icv, intracerebroventricular injection; ns, not studied; HPC, intra-hippocampal administration; BLA, intra-basolateral amygdala administration; DLS, dorsolateral septum; vlPAG, ventrolateral periaqueductal gray; Ren-A, fear renewal in conditioning context; ag, agonist; ant, antagonist, KO, knock-out;

###### 

Glucocorticoid signaling in fear extinction (preclinical studies).

  *Facilitating glucocorticoid signaling*                                                                                                                
  ------------------------------------------------ ------------------------------------- ------------------------------------- ------------------- ----- -------------------------------
  Corticosterone (GR/MR ag)                        ns                                    \+[1](#TFN81){ref-type="table-fn"}    No effect (Re-in)   ip    ([@R35])
                                                   ns                                    −[2](#TFN82){ref-type="table-fn"}     ns                  ip    ([@R107])
  Dexamethasone (GR ag)                            ns                                    \+                                    ns                  ip    ([@R376]); ([@R551], [@R552])
  RU28362 (GR ag)                                  ns                                    \+                                    ns                  AMY   ([@R551])
  Ganoxolone (allopregnanolone analog)             +\*[3](#TFN83){ref-type="table-fn"}   +\*[3](#TFN83){ref-type="table-fn"}   ns                  ip    ([@R413])
  *Inhibiting glucocorticoid signaling*                                                                                                                  
  Metyrapone (CORT/cortisol synthesis inhibitor)   No effect                             −                                     −\*                 sc    ([@R27]); ([@R83])
                                                   ns                                    −                                     ns                  sc    ([@R35]); ([@R551], [@R552])
  Mifepristone (GR and progesterone ant)           ns                                    −                                     ns                  AMY   ([@R551])

Drug administration following extinction training;

in adolescent but not adult rats if exposed to CORT one week prior to (drug free) testing; adults also show impaired extinction retrieval if they were exposed to one week of CORT in their adolescence;

socially isolated mice, CAVE ganoxolone was administered following a reactivation session 24h prior extinction training.

+, Improved; -, impaired; ip, intraperitoneal injection; sc, subcutaneous injection; ns, not studied; AMY, intra-amygdala administration; Re-in, reinstatement; ag, agonist; ant, antagonist; GR, glucocorticoid receptor; MR, mineralocorticoid receptor; CORT, corticosteroid.

###### 

Human trials: glucocorticoids combined with CBT.

  --------------------------------------------------------------------------------------------------------------------------------------------------------------
  Disorder                Study design                                              Outcome (compared to placebo control group)                      Reference
  ----------------------- --------------------------------------------------------- ---------------------------------------------------------------- -----------
  Social phobia           Cortisone or placebo administered orally 1 h before a\    Reduced self-reported fear during anticipation and exposure      ([@R481])
                          socio-evaluative stressor                                                                                                  

  Spider phobia           Cortisol or placebo administered orally 1 h before\       Progressive reduction of stimulus-induced fear\                  ([@R481])
                          exposure to a spider photograph in 6 sessions\            Reduction of fear was maintained also 2 days following\          
                          distributed over 2 weeks                                  session ending (OFF-drug)                                        

  Spider phobia           Cortisol or placebo administered orally 1 h before 2\     Significant decrease in phobic symptoms assessed with the\       ([@R482])
                          exposure therapy sessions\                                Fear of Spiders Questionnaire\                                   
                          Follow-up after 1 month                                   Cortisol-treated patients reported significantly less anxiety\   
                                                                                    during exposure to living spiders at follow-up                   

  Acrophobia              Cortisol or placebo was administered orally 1 h before\   Greater reduction in fear of heights measured with the\          ([@R104])
                          virtual reality exposure to heights\                      acrophobia questionnaire both at post-treatment and at\          
                          Follow-up after 1 month                                   follow-up                                                        

  PTSD (combat-related)   Memory reactivation task followed by intravenous\         Reduced PTSD symptomatic in cortisol-treated patients\           ([@R496])
                          administration of cortisol or saline\                     No differences between cortisol and saline treated patients\     
                          Follow-up after 1 month                                   (initial improvement was lost after 1 month)                     

  PTSD                    10 weekly sessions of prolonged exposure therapy,\        Accelerated and greater decline in PTSD symptoms\                ([@R558])
                          cortisol or placebo 30min prior session 3--10             Caveat -- includes only 2 patients (1 cortisol/1 placebo)        
  --------------------------------------------------------------------------------------------------------------------------------------------------------------

###### 

Neurotrophins and miscellaneous targets in fear extinction (preclinical studies).

  *Neurotrophins*                                                                                                                                                                                                                                                    
  --------------------------------------------------------- ---------------------------------------- ----------------------------------------------------------------------- ----------------------------------------------------------------------------- --------- ----------------------
  FGF2                                                      (+)[\#](#TFN92){ref-type="table-fn"}     \+                                                                      ns                                                                            sc        ([@R165])
                                                            ns                                       \+[1](#TFN85){ref-type="table-fn"}                                      \+ (Re-in) (Ren-A)                                                            sc        ([@R165], [@R166])
                                                            ns                                       \+[1](#TFN85){ref-type="table-fn"}                                      \+ (Ren-A)                                                                    BLA       ([@R168])
  BDNF                                                      No training                              \+[\*\*](#TFN90){ref-type="table-fn"}[2](#TFN86){ref-type="table-fn"}   No effect (Re-in)                                                             IL        ([@R410]); ([@R442])
                                                            No training                              No effect[2](#TFN86){ref-type="table-fn"}                               ns                                                                            PL        ([@R442])
  7.8-Dihydroxyflavone                                      (+)[\*](#TFN89){ref-type="table-fn"}     No effect                                                               (+) (Re-in)                                                                   ip        ([@R13])
                                                            No effect                                No effect[\*](#TFN89){ref-type="table-fn"}                              \+ (Ren-A)                                                                    ip        ([@R22])
  Lentiviral transfected dominant negative form of TrkB     No effect                                −                                                                       ns                                                                            BLA       ([@R76])
  BDNF KD in HPC                                            −                                        ns                                                                      ns                                                                            No drug   ([@R204])
  Val66Met BDNF SNP                                         −                                        ns                                                                      ns                                                                            No drug   ([@R480])
  BDNF +/− KO                                               −[\*\*\*](#TFN91){ref-type="table-fn"}   −[\*\*\*](#TFN91){ref-type="table-fn"}                                  ns                                                                            No drug   ([@R420])
  BDNF antibody                                             −                                        −                                                                       ns                                                                            IL        ([@R442])
                                                            No effect                                No effect                                                               ns                                                                            PL        ([@R442])
  BDNF KO in forebrain                                      ns                                       No effect[\#](#TFN92){ref-type="table-fn"}                              ns                                                                            PL        ([@R77])
  Methylene blue, nitric oxide, histamine, and LTCCs                                                                                                                                                                                                                 
  Methylene blue                                            ns                                       \+[1](#TFN85){ref-type="table-fn"}                                      ns                                                                            ip        ([@R161])
                                                            ns                                       ns                                                                      \+[1](#TFN85){ref-type="table-fn"}[\*](#TFN89){ref-type="table-fn"} (Ren-A)   ip        ([@R544])
  Histamine                                                 ns                                       \+[1](#TFN85){ref-type="table-fn"}                                      ns                                                                            CA1       ([@R37])
  Dimaprit (H2 ag)                                          ns                                       \+[1](#TFN85){ref-type="table-fn"}                                      ns                                                                            CA1       ([@R37])
  Ranitidine (H2 ant)                                       ns                                       −[1](#TFN85){ref-type="table-fn"}                                       ns                                                                            CA1       ([@R138])
                                                            ns                                       −[1](#TFN85){ref-type="table-fn"}                                       ns                                                                            BLA       ([@R138])
                                                            ns                                       −[1](#TFN85){ref-type="table-fn"}                                       ns                                                                            PFC       ([@R138])
  SKF9188 (histamine methyl-transferase inhibitor)          ns                                       \+[1](#TFN85){ref-type="table-fn"}                                      ns                                                                            CA1       ([@R138])
                                                            ns                                       \+[1](#TFN85){ref-type="table-fn"}                                      ns                                                                            BLA       ([@R138])
                                                            ns                                       \+[1](#TFN85){ref-type="table-fn"}                                      ns                                                                            PFC       ([@R138])
  L-NAME (nNOS inhibitor)[4](#TFN88){ref-type="table-fn"}   −                                        −                                                                       ns                                                                            ip        ([@R308])
  CamKII-Cre Cav1.2 KO                                      No effect                                ns                                                                      ns                                                                            No drug   ([@R334])
  Cav1.3 KO                                                 No effect                                ns                                                                      ns                                                                            No drug   ([@R52])
                                                            No effect                                ns                                                                      ns                                                                            No drug   ([@R332])
  Nifedipine (LTCC ant)                                     −                                        ns                                                                      ns                                                                            ip        ([@R55])
                                                            No effect                                ns                                                                      ns                                                                            icv       ([@R52])
                                                            No effect                                −                                                                       ns                                                                            BLA       ([@R93])
                                                            ns                                       −[1](#TFN85){ref-type="table-fn"}                                       ns                                                                            HPC       ([@R100])
  Verapamil (VGCC ant)                                      No effect                                −                                                                       ns                                                                            BLA       ([@R93])

Drug administration following extinction training;

drug administration 24 h prior extinction retrieval

drug administration 30 min prior extinction retrieva

ABA scheme, 40 mg/kg.

Facilitates rescue of impaired fear extinction;

facilitates extinction of remote memories,

only in older animals (7 months), younger ones (2 months) are not affected,

reduced fear expression at the beginning of extinction training.

+, improved; -, impaired; (+) or (−), only minor effects; ip, intraperitoneal injection; sc, subcutanous injection; icv, intracerebroventricular injection; ns, not studied; HPC, intra-hippocampal administration; BLA, intra-basolateral amygdala administration; IL, infralimbic cortex; PL, prelimbic cortex; CA1, cornu ammonis 1; Ren-A, Fear renewal in conditioning context; SR, spontaneous recovery; Re-in, reinstatement; ag, agonist; ant, antagonist, KO, knock-out;

###### 

Studies showing that HDAC inhibitors augment exposure-based fear extinction and rescue extinction learning deficits.

  Drug/manipulat                         Extinction training                      Extinction retrieval                                                   Longterm extinction   Route     Reference
  -------------------------------------- ---------------------------------------- ---------------------------------------------------------------------- --------------------- --------- -----------
  HDAC1 KO (HPC)                         ns                                       −[\#](#TFN97){ref-type="table-fn"}                                     ns                    No drug   ([@R19])
  HDAC2 KO in forebrain CamKII neurons   ns                                       \+[\*](#TFN94){ref-type="table-fn"}[\#](#TFN97){ref-type="table-fn"}   ns                    No drug   ([@R360])
  Vorinostat/SAHA                        ns                                       \+                                                                     ns                    ip        ([@R146])
                                         ns                                       \+ [\*\*](#TFN95){ref-type="table-fn"}                                 ns                    ip        ([@R326])
                                         ns                                       \+ [\*\*](#TFN95){ref-type="table-fn"}                                 ns                    ip        ([@R187])
  TSA (trichostatin A)                   ns                                       \+[\*](#TFN94){ref-type="table-fn"}                                    ns                    ip, HPC   ([@R274])
  Sodium butyrate                        −                                        \+                                                                     \+ (SR)               ip, HPC   ([@R486])
                                         ns                                       \+                                                                     ns                    ip        ([@R233])
                                         ns                                       \+                                                                     ns                    ip, HPC   ([@R274])
  Valproic acid                          −                                        \+[\*](#TFN94){ref-type="table-fn"}                                    ns                    ip        ([@R45])
                                                                                  \+[\*](#TFN94){ref-type="table-fn"}                                    \+ (Ren-A)            ip        ([@R44])
                                         \+ [\*\*](#TFN95){ref-type="table-fn"}   \+ [\*\*](#TFN95){ref-type="table-fn"}                                 \+ (SR, Ren-N)        ip        ([@R536])
  MS-275 (entinostat)                    −                                        \+ [\*\*](#TFN95){ref-type="table-fn"}                                 \+ (SR, Ren-N)        ip        ([@R536])
  Cl-994                                 ns                                       \+ [\*\*\*](#TFN96){ref-type="table-fn"}                               \+ (SR)               ip        ([@R163])
  FTY720 (fingolimod)                    −                                        \+ [\*\*](#TFN95){ref-type="table-fn"}                                 ns                    ip        ([@R187])

Partial extinction training: reduction of fear during the extinction training session was not to pre-conditioning levels,

facilitates rescue of impaired fear extinction;

facilitate remote memories combined with memory re-consolidation update paradigm;

extinction protocol based on a re-consolidation/update paradigm

+, Improved;-, impaired; ip, intraperitoneal injection; ns, not studied; HPC, intra-hippocampal administration; Ren-A, Fear renewal in the conditioning context; Ren-N, Fear renewal in a novel context; SR, spontaneous recovery; \# reduced freezing levels at the beginning of extinction training

###### Box 1 Why pharmacological augmentation of extinction?

A limitation of extinction-based exposure therapy is that patients can often relapse with the passage of time, with changes in context (out of the therapy context), or under conditions of stress or other provocations, such as experiencing trauma reminders. In the parlance of learning theory, extinction memories are labile and fragile. A key goal for pharmacotherapy, therefore, is to identify compounds that overcome this fragility, by bolstering the formation, persistence and possibly context independence of extinction memories. One approach to achieving this goal is to use drugs as adjuncts to exposure therapy (cognitive enhancers) as a way to augment the extinction learning process. In this review, we discuss the various neurochemical and molecular signaling pathways that have been targeted to this end. On the one hand, there remain significant challenges to overcome, including the selective targeting of extinction-related processes without concurrent effects on original fear memories. On the other hand, there are clearly a plethora of potentially promising avenues to pursue, and we are optimistic that real advances can be made in treating trauma-related disorders.
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